Bcl-2	B-protein
-mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
lymphocytes	I-protein
(	O
NFAT	B-protein
)	O
-induced	O
Fas	B-protein
ligand	O
transcription	O
.	O

Bcl-2	B-protein
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl-2	B-protein
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	O
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl-2	B-protein
family	I-protein
such	O
as	O
Bax	B-protein
and	O
Bad	B-protein
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B-protein
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	B-protein
/Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
-dependent	O
manner	O
;	O
antibody	O
to	O
FasL	B-protein
inhibits	O
paclitaxel-induced	O
apoptosis	O
.	O

We	O
have	O
found	O
that	O
Bcl-2	B-protein
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-induced	O
expression	O
of	O
FasL	B-protein
and	O
blocks	O
paclitaxel-induced	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl-2	B-protein
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
lymphocytes	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
microtubule	B-protein
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium-dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	B-protein
to	O
move	O
to	O
the	O
nucleus	O
.	O

Without	O
NFAT	B-protein
nuclear	O
translocation	O
,	O
the	O
FasL	B-protein
gene	O
is	O
not	O
transcribed	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B-protein
function	O
kill	O
cells	O
at	O
least	O
in	O
part	O
through	O
the	O
induction	O
of	O
FasL	B-protein
.	O

Furthermore	O
,	O
Bcl-2	B-protein
antagonizes	O
drug-induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	B-protein
activation	O
,	O
blocking	O
NFAT	B-protein
nuclear	O
translocation	O
,	O
and	O
preventing	O
FasL	B-protein
expression	O
.	O

The	O
effects	O
of	O
Bcl-2	B-protein
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl-2	B-protein
.	O

Phosphorylated	O
Bcl-2	B-protein
can	O
not	O
bind	O
calcineurin	B-protein
,	O
and	O
NFAT	B-protein
activation	O
,	O
FasL	B-protein
expression	O
,	O
and	O
apoptosis	O
can	O
occur	O
after	O
Bcl-2	B-protein
phosphorylation	O
.	O

Bcl-2-mediated	NULL
Drug	NULL
Resistance	NULL
:	NULL
Inhibition	NULL
of	NULL
Apoptosis	NULL
by	NULL
Blocking	NULL
Nuclear	NULL
Factor	NULL
of	NULL
Activated	NULL
T	NULL
Lymphocytes	NULL
(	NULL
NFAT	NULL
)	NULL
-induced	NULL
Fas	NULL
Ligand	NULL
Transcription	NULL
By	NULL
R	NULL
akesh	NULL
K.	NULL
Srivastava	NULL
,	NULL
*	NULL
Carl	NULL
Y.	NULL
Sasaki	NULL
,	NULL
*	NULL
J.	NULL
Marie	NULL
Hardwick	NULL
,	NULL
*	NULL
and	NULL
Dan	NULL
L.	NULL
Longo*	NULL
From	NULL
the	NULL
*	NULL
Laboratory	NULL
of	NULL
Immunology	NULL
,	NULL
N	NULL
ational	NULL
Institute	NULL
on	NULL
A	NULL
ging	NULL
N	NULL
ational	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Baltimore	NULL
,	NULL
Maryland	NULL
21224-6825	NULL
;	NULL
and	NULL
the	NULL
*Department	NULL
of	NULL
Molecular	NULL
Biology	NULL
and	NULL
Immundlogy	NULL
,	NULL
Johns	NULL
Hopkins	NULL
School	NULL
of	NULL
Public	NULL
Health	NULL
,	NULL
Baltimore	NULL
,	NULL
Maryland	NULL
21205	NULL
Summary	NULL
Bcl-2	NULL
inhibits	NULL
apoptosis	NULL
induced	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
stimuli	NULL
,	NULL
including	NULL
chemotherapy	NULL
drugs	NULL
and	NULL
glu-cocorticoids	NULL
.	NULL

It	NULL
is	NULL
generally	NULL
accepted	NULL
that	NULL
Bel-2	NULL
exerts	NULL
its	NULL
antiapoptotic	NULL
effects	NULL
mainly	NULL
by	NULL
dimer-izing	NULL
with	NULL
proapoptotic	NULL
members	NULL
of	NULL
the	NULL
Bcel-2	NULL
family	NULL
such	NULL
as	NULL
Bax	NULL
and	NULL
Bad	NULL
.	NULL

However	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
the	NULL
antiapoptotic	NULL
effects	NULL
is	NULL
unclear	NULL
.	NULL

Paclitaxel	NULL
and	NULL
other	NULL
drugs	NULL
that	NULL
disturb	NULL
microtubule	NULL
dynamics	NULL
kill	NULL
cells	NULL
in	NULL
a	NULL
Fay	NULL
Fas	NULL
ligand	NULL
(	NULL
FasL	NULL
)	NULL
-dependent	NULL
manner	NULL
;	NULL
antibody	NULL
to	NULL
FasL	NULL
inhibits	NULL
paclitaxel-	NULL
induced	NULL
apoptosis	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
Bel-2	NULL
overexpression	NULL
leads	NULL
to	NULL
the	NULL
prevention	NULL
of	NULL
chemotherapy	NULL
(	NULL
paclitaxel	NULL
)	NULL
-induced	NULL
expression	NULL
of	NULL
FasL	NULL
and	NULL
blocks	NULL
paclitaxel-induced	NULL
apoptosis	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
this	NULL
effect	NULL
is	NULL
that	NULL
Bel-2	NULL
prevents	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFAT	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
lymphocytes	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
activated	NULL
by	NULL
microtubule	NULL
damage	NULL
)	NULL
by	NULL
binding	NULL
and	NULL
sequestering	NULL
calcineurin	NULL
,	NULL
a	NULL
calcium-dependent	NULL
phosphatase	NULL
that	NULL
must	NULL
dephosphory-late	NULL
NFAT	NULL
to	NULL
move	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

Without	NULL
NFAT	NULL
nuclear	NULL
translocation	NULL
,	NULL
the	NULL
FasL	NULL
gene	NULL
is	NULL
not	NULL
transcribed	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
paclitaxel	NULL
and	NULL
other	NULL
drugs	NULL
that	NULL
disturb	NULL
microtubule	NULL
function	NULL
kill	NULL
cells	NULL
at	NULL
least	NULL
in	NULL
part	NULL
through	NULL
the	NULL
induction	NULL
of	NULL
FasL	NULL
.	NULL

Furthermore	NULL
,	NULL
Bel-2	NULL
antagonizes	NULL
drug-induced	NULL
apoptosis	NULL
by	NULL
inhibiting	NULL
calcineurin	NULL
activation	NULL
,	NULL
blocking	NULL
NFAT	NULL
nuclear	NULL
translocation	NULL
,	NULL
and	NULL
pre	NULL
venting	NULL
FasL	NULL
expression	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
Bel-2	NULL
can	NULL
be	NULL
overcome	NULL
,	NULL
at	NULL
least	NULL
partially	NULL
,	NULL
through	NULL
phos	NULL
phorylation	NULL
of	NULL
Bcel-2	NULL
.	NULL

Phosphorylated	NULL
Bel-2	NULL
can	NULL
not	NULL
bind	NULL
calcineurin	NULL
,	NULL
and	NULL
NFAT	NULL
activation	NULL
,	NULL
FasL	NULL
expression	NULL
,	NULL
and	NULL
apoptosis	NULL
can	NULL
occur	NULL
after	NULL
Bel-2	NULL
phosphorylation	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
-	NULL
Fas	NULL
ligand	NULL
«	NULL
apoptosis	NULL
«	NULL
NFAT	NULL
*	NULL
Bel-2	NULL
«	NULL
paclitaxel	NULL
inding	NULL
of	NULL
Fas	NULL
ligand	NULL
(	NULL
FasL	NULL
)	NULL
or	NULL
an	NULL
anti-	NULL
Fas	NULL
antibody	NULL
to	NULL
Fas	NULL
(	NULL
APO	NULL
-1	NULL
or	NULL
CD-95	NULL
)	NULL
causes	NULL
apoptosis	NULL
in	NULL
Fas-bearing	NULL
cells	NULL
.	NULL

Fas	NULL
is	NULL
ubiquitously	NULL
expressed	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
(	NULL
1-3	NULL
)	NULL
,	NULL
but	NULL
the	NULL
expression	NULL
of	NULL
FasL	NULL
is	NULL
much	NULL
more	NULL
restricted	NULL
(	NULL
4-7	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
expression	NULL
of	NULL
FasL	NULL
was	NULL
originally	NULL
considered	NULL
to	NULL
be	NULL
restricted	NULL
to	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
NK	NULL
cells	NULL
,	NULL
FasL	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
Sertoli	NULL
cells	NULL
and	NULL
cells	NULL
of	NULL
the	NULL
eye	NULL
,	NULL
liver	NULL
,	NULL
and	NULL
kidney	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
functional	NULL
FasL	NULL
by	NULL
some	NULL
tissues	NULL
contributes	NULL
to	NULL
their	NULL
immune-privileged	NULL
status	NULL
by	NULL
preventing	NULL
the	NULL
infiltration	NULL
of	NULL
inflammatory	NULL
leukocytes	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
constitutive	NULL
FasL	NULL
expression	NULL
has	NULL
been	NULL
detected	NULL
on	NULL
some	NULL
tumor	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
it	NULL
may	NULL
function	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
Fas-expressing	NULL
immune	NULL
cells	NULL
when	NULL
they	NULL
attempt	NULL
to	NULL
enter	NULL
the	NULL
tumor	NULL
(	NULL
11-14	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
it	NULL
has	NULL
been	NULL
postulated	NULL
that	NULL
the	NULL
Fay	NULL
FasL	NULL
system	NULL
has	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
many	NULL
diseases	NULL
such	NULL
as	NULL
hepatitis	NULL
,	NULL
insulin-dependent	NULL
diabetes	NULL
,	NULL
cancer	NULL
,	NULL
and	NULL
thyroiditis	NULL
(	NULL
Hashimoto	NULL
's	NULL
disease	NULL
)	NULL
(	NULL
15-21	NULL
)	NULL
.	NULL
'	NULL

A	NULL
bbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
L	NULL
,	NULL
ligand	NULL
;	NULL
NFAT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
lymphocytes	NULL
;	NULL
PI	NULL
,	NULL
propidium	NULL
iodide	NULL
.	NULL

The	NULL
antiapoptotic	NULL
gene	NULL
Bel-2	NULL
protects	NULL
cancer	NULL
cells	NULL
from	NULL
apoptosis	NULL
induced	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
anticancer	NULL
agents	NULL
(	NULL
22-25	NULL
)	NULL
.	NULL

The	NULL
precise	NULL
mechanism	NULL
by	NULL
which	NULL
Bcel-2	NULL
inhibits	NULL
drug-induced	NULL
apoptosis	NULL
is	NULL
unknown	NULL
.	NULL

Mice	NULL
in	NULL
which	NULL
wild-type	NULL
Bcel-2	NULL
was	NULL
overexpressed	NULL
documented	NULL
extended	NULL
cell	NULL
survival	NULL
rather	NULL
than	NULL
increased	NULL
proliferation	NULL
and	NULL
led	NULL
to	NULL
an	NULL
accumulation	NULL
of	NULL
lymphocytes	NULL
that	NULL
eventually	NULL
progressed	NULL
to	NULL
B	NULL
and	NULL
T	NULL
cell	NULL
malignancy	NULL
after	NULL
subsequent	NULL
genetic	NULL
changes	NULL
(	NULL
26-28	NULL
)	NULL
.	NULL

Loss	NULL
of	NULL
function	NULL
studies	NULL
that	NULL
knocked	NULL
out	NULL
the	NULL
Bcel-2	NULL
or	NULL
Bel-X	NULL
;	NULL
,	NULL
death	NULL
suppressors	NULL
demonstrated	NULL
the	NULL
loss	NULL
of	NULL
cells	NULL
from	NULL
selected	NULL
lineages	NULL
(	NULL
29-31	NULL
)	NULL
.	NULL

Although	NULL
hematopoietic	NULL
lineages	NULL
appear	NULL
to	NULL
develop	NULL
normally	NULL
in	NULL
the	NULL
Bel-mice	NULL
,	NULL
they	NULL
are	NULL
unable	NULL
to	NULL
maintain	NULL
homeostasis	NULL
of	NULL
lymphocytes	NULL
because	NULL
of	NULL
excess	NULL
apoptotic	NULL
loss	NULL
of	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

Micro-tubule-stabilizing	NULL
agents	NULL
such	NULL
as	NULL
paclitaxel	NULL
and	NULL
docetaxel	NULL
and	NULL
microtubule-disrupting	NULL
drugs	NULL
such	NULL
as	NULL
vincristine	NULL
,	NULL
vinblas	NULL
tine	NULL
,	NULL
and	NULL
colchicine	NULL
have	NULL
antimitotic	NULL
and	NULL
inducing	NULL
activity	NULL
(	NULL
24	NULL
,	NULL
25	NULL
,	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
screening	NULL
of	NULL
a	NULL
library	NULL
of	NULL
phage-displayed	NULL
peptides	NULL
identified	NULL
human	NULL
Bel-2	NULL
as	NULL
a	NULL
pacli-taxel-binding	NULL
protein	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Paclitaxel	NULL
induces	NULL
Bel-2	NULL
phos	NULL
phorylation	NULL
and	NULL
apoptosis	NULL
in	NULL
human	NULL
leukemic	NULL
,	NULL
breast	NULL
,	NULL
and	NULL
253	NULL
The	NULL
Journal	NULL
of	NULL
Experimental	NULL
Medicine	NULL
«	NULL
Volume	NULL
190	NULL
,	NULL
Number	NULL
2	NULL
,	NULL
July	NULL
19	NULL
,	NULL
1999	NULL
253-265	NULL
http	NULL
:	NULL
//	NULL
www.jem.org	NULL
prostate	NULL
cancer	NULL
cells	NULL
(	NULL
24	NULL
,	NULL
25	NULL
,	NULL
35	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
phosphorylation	NULL
of	NULL
Bel-2	NULL
may	NULL
inhibit	NULL
Bel-2	NULL
function	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
Bcel-2	NULL
function	NULL
by	NULL
phosphorylation	NULL
has	NULL
been	NULL
demonstrated	NULL
at	NULL
the	NULL
level	NULL
of	NULL
formation	NULL
of	NULL
Bel-2-Bax	NULL
hetero-dimers	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
Bel-2	NULL
exerts	NULL
its	NULL
biological	NULL
effects	NULL
in	NULL
additional	NULL
protein	NULL
interactions	NULL
distinct	NULL
from	NULL
those	NULL
with	NULL
proapoptotic	NULL
family	NULL
members	NULL
.	NULL

A	NULL
growing	NULL
body	NULL
of	NULL
evidence	NULL
suggests	NULL
that	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
lymphocytes	NULL
(	NULL
NFAT	NULL
)	NULL
is	NULL
expressed	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
tissues	NULL
in	NULL
addition	NULL
to	NULL
lymphocytes	NULL
(	NULL
36	NULL
)	NULL
.	NULL

To	NULL
date	NULL
,	NULL
NFAT	NULL
expression	NULL
or	NULL
function	NULL
has	NULL
been	NULL
described	NULL
in	NULL
several	NULL
types	NULL
of	NULL
nonlymphoid	NULL
cells	NULL
including	NULL
mast	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
,	NULL
endothelial	NULL
cells	NULL
(	NULL
38	NULL
)	NULL
,	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
(	NULL
39	NULL
)	NULL
,	NULL
and	NULL
neuronal	NULL
cells	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
messenger	NULL
RN	NULL
As	NULL
of	NULL
distinct	NULL
NFAT	NULL
isoforms	NULL
are	NULL
expressed	NULL
in	NULL
a	NULL
tissue-specific	NULL
manner	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Linette	NULL
et	NULL
al	NULL
.	NULL

(	NULL
41a	NULL
)	NULL
have	NULL
documented	NULL
a	NULL
regulatory	NULL
interaction	NULL
between	NULL
Bcel-2	NULL
expression	NULL
and	NULL
NFAT	NULL
activation	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
NFAT	NULL
regulates	NULL
the	NULL
transcription	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
apoptosis	NULL
and	NULL
that	NULL
antiapoptotic	NULL
Bel-2	NULL
family	NULL
members	NULL
act	NULL
in	NULL
part	NULL
by	NULL
interfering	NULL
with	NULL
NFAT	NULL
-induced	NULL
gene	NULL
transcription	NULL
.	NULL

One	NULL
candidate	NULL
proapoptotic	NULL
gene	NULL
that	NULL
is	NULL
regulated	NULL
by	NULL
NFAT	NULL
is	NULL
FasL	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
FasL	NULL
gene	NULL
is	NULL
regulated	NULL
at	NULL
least	NULL
in	NULL
part	NULL
by	NULL
an	NULL
interaction	NULL
of	NULL
NFAT	NULL
proteins	NULL
with	NULL
the	NULL
FasL	NULL
promoter	NULL
(	NULL
42-44	NULL
)	NULL
.	NULL

Transcription	NULL
mediated	NULL
by	NULL
NFAT	NULL
is	NULL
regulated	NULL
tightly	NULL
in	NULL
response	NULL
to	NULL
second	NULL
messengers	NULL
such	NULL
as	NULL
calcium	NULL
.	NULL

Increased	NULL
intracellular	NULL
C	NULL
#	NULL
+	NULL
stimulates	NULL
calcineurin-dependent	NULL
dephosphorylation	NULL
of	NULL
cytoplasmic	NULL
NFAT	NULL
,	NULL
leading	NULL
to	NULL
its	NULL
nuclear	NULL
translocation	NULL
(	NULL
45	NULL
)	NULL
.	NULL

T	NULL
cell	NULL
activation	NULL
was	NULL
found	NULL
to	NULL
induce	NULL
NFAT	NULL
binding	NULL
to	NULL
the	NULL
FasL	NULL
enhancer	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
Bel-2	NULL
mediates	NULL
its	NULL
antiapoptotic	NULL
effects	NULL
not	NULL
only	NULL
by	NULL
forming	NULL
heterodimers	NULL
with	NULL
proapoptotic	NULL
Bcl-2	NULL
family	NULL
members	NULL
but	NULL
also	NULL
through	NULL
antagonism	NULL
of	NULL
NFAT	NULL
activation	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
examine	NULL
the	NULL
intracellular	NULL
mechanisms	NULL
by	NULL
which	NULL
Bel-2	NULL
inhibits	NULL
apoptosis	NULL
induced	NULL
by	NULL
microtubule-damaging	NULL
drugs	NULL
(	NULL
paclitaxel	NULL
,	NULL
vincristine	NULL
,	NULL
and	NULL
vinblastine	NULL
)	NULL
in	NULL
Jurkat	NULL
T	NULL
lymphocytes	NULL
and	NULL
breast	NULL
carcinoma	NULL
cells	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
expression	NULL
of	NULL
FasL	NULL
plays	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
apoptosis	NULL
induced	NULL
by	NULL
microtubule-damaging	NULL
drugs	NULL
.	NULL

Upon	NULL
exposure	NULL
to	NULL
such	NULL
drugs	NULL
,	NULL
FasL	NULL
is	NULL
rapidly	NULL
expressed	NULL
.	NULL

Antibody	NULL
to	NULL
FasL	NULL
inhibits	NULL
paclitaxel-induced	NULL
apoptosis	NULL
.	NULL

In	NULL
cells	NULL
overexpressing	NULL
Bel-2	NULL
,	NULL
FasL	NULL
expression	NULL
is	NULL
blocked	NULL
upon	NULL
exposure	NULL
to	NULL
low	NULL
doses	NULL
of	NULL
paclitaxel	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
Bel-2	NULL
inhibits	NULL
FasL	NULL
expression	NULL
is	NULL
indirect	NULL
;	NULL
Bel-2	NULL
binds	NULL
to	NULL
calcineurin	NULL
and	NULL
inhibits	NULL
its	NULL
dephosphorylation	NULL
and	NULL
release	NULL
of	NULL
NFAT	NULL
.	NULL

Thus	NULL
,	NULL
NFAT	NULL
is	NULL
unable	NULL
to	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
FasL	NULL
transcription	NULL
does	NULL
not	NULL
occur	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
Bel-2	NULL
acts	NULL
to	NULL
block	NULL
drug-	NULL
or	NULL
activation-induced	NULL
apoptosis	NULL
.	NULL

Very	NULL
high	NULL
doses	NULL
of	NULL
paclitaxel	NULL
can	NULL
overcome	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
Bel-2	NULL
on	NULL
NFAT	NULL
nuclear	NULL
translocation	NULL
.	NULL

High	NULL
doses	NULL
of	NULL
paclitaxel	NULL
lead	NULL
to	NULL
Bel-2	NULL
phos	NULL
phorylation	NULL
and	NULL
dissociation	NULL
from	NULL
calcineurin	NULL
,	NULL
which	NULL
allows	NULL
NFAT	NULL
activation	NULL
and	NULL
FasL	NULL
expression	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Reagents	NULL
.	NULL

Paclitaxel	NULL
,	NULL
vincristine	NULL
,	NULL
vinblastine	NULL
,	NULL
ascomycin	NULL
,	NULL
and	NULL
6-diamidino-2-phenylindole	NULL
(	NULL
DAPI	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co	NULL
.	NULL

Secondary	NULL
antibody	NULL
(	NULL
donkey	NULL
anti-goat	NULL
IgG	NULL
)	NULL
conjugated	NULL
with	NULL
Alexa-488	NULL
and	NULL
1,2-bis	NULL
(	NULL
o-aminophenoxy	NULL
)	NULL
ethane-N	NULL
,	NULL
N	NULL
,	NULL
N	NULL
'	NULL
,	NULL
N	NULL
'	NULL
-tetraacetic	NULL
acid	NULL
tetra	NULL
(	NULL
acetoxymethyl	NULL
)	NULL
ester	NULL
(	NULL
BAPT	NULL
A-	NULL
AM	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Molecular	NULL
Probes	NULL
,	NULL
Inc.	NULL
and	NULL
Calbiochem	NULL
Corp.	NULL
,	NULL
respectively	NULL
.	NULL

Antibodies	NULL
against	NULL
Bcel-2	NULL
,	NULL
B-actin	NULL
,	NULL
Fas	NULL
,	NULL
and	NULL
FasL	NULL
were	NULL
purchased	NULL
from	NULL
Transduction	NULL
Labs	NULL
.	NULL

FasL-neutralizing	NULL
antibody	NULL
was	NULL
purchased	NULL
from	NULL
PharMingen	NULL
.	NULL

Fas-blocking	NULL
antibody	NULL
was	NULL
purchased	NULL
from	NULL
Alexis	NULL
.	NULL

Antibody	NULL
against	NULL
NFAT	NULL
was	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

Enhanced	NULL
chemiluminescent	NULL
Western	NULL
blot	NULL
detection	NULL
reagents	NULL
were	NULL
purchased	NULL
from	NULL
Amersham	NULL
Life	NULL
Sciences	NULL
,	NULL
Inc	NULL
.	NULL

The	NULL
chemiluminescent	NULL
reporter	NULL
gene	NULL
assay	NULL
system	NULL
for	NULL
the	NULL
combined	NULL
detection	NULL
of	NULL
luciferase	NULL
and	NULL
B-galactosidase	NULL
was	NULL
purchased	NULL
from	NULL
Tropix	NULL
,	NULL
Inc	NULL
.	NULL

Cells	NULL
and	NULL
Culture	NULL
Conditions	NULL
.	NULL

-	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
breast	NULL
carcinoma	NULL
MDA-MB-231	NULL
and	NULL
MCF-7	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
tissue	NULL
culture	NULL
medium	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Inc.	NULL
)	NULL
supplemented	NULL
with	NULL
2	NULL
mM	NULL
1-glutamine	NULL
,	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
and	NULL
1	NULL
%	NULL
penicillin-streptomycin	NULL
mixture	NULL
at	NULL
37°C	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

Transfection	NULL
of	NULL
Bd-2	NULL
Genes	NULL
.	NULL

Jurkat	NULL
cells	NULL
and	NULL
MDA-MB-231	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
wild-type	NULL
Bcl-2	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
pSFFVneo-Bcl-2	NULL
,	NULL
pSFFVneo-Bcl-X	NULL
;	NULL
,	NULL
and	NULL
pSFFV	NULL
Neo	NULL
plasmids	NULL
were	NULL
provided	NULL
by	NULL
Dr.	NULL
Stanley	NULL
Korsmeyer	NULL
(	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
JT/	NULL
mut	NULL
CD95	NULL
)	NULL
harboring	NULL
a	NULL
Fas	NULL
mutant	NULL
lacking	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
were	NULL
provided	NULL
by	NULL
Dr.	NULL
Gary	NULL
A.	NULL
Koretzky	NULL
(	NULL
University	NULL
of	NULL
Iowa	NULL
,	NULL
Iowa	NULL
City	NULL
,	NULL
IA	NULL
)	NULL
and	NULL
described	NULL
elsewhere	NULL
(	NULL
46	NULL
)	NULL
.	NULL

MDA-MB-	NULL
231	NULL
cells	NULL
were	NULL
also	NULL
transfected	NULL
with	NULL
either	NULL
pSFFVneo-	NULL
ABH4	NULL
Bel-2	NULL
or	NULL
pSFFVneo-Aloop	NULL
Bcel-2	NULL
plasmid	NULL
using	NULL
lipofectine	NULL
(	NULL
GIBCO	NULL
BRL	NULL
)	NULL
.	NULL

Trans	NULL
duced	NULL
cells	NULL
were	NULL
selected	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
1	NULL
mg/	NULL
ml	NULL
G418	NULL
(	NULL
Geneticin	NULL
;	NULL
GIBCO	NULL
BRL	NULL
)	NULL
for	NULL
1	NULL
mo	NULL
.	NULL

Clones	NULL
expressing	NULL
the	NULL
highest	NULL
levels	NULL
of	NULL
Bcel-2	NULL
were	NULL
used	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

For	NULL
transient	NULL
transfection	NULL
,	NULL
lipofectine	NULL
reagent	NULL
was	NULL
used	NULL
to	NULL
transfect	NULL
the	NULL
plasmid	NULL
as	NULL
per	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
GIBCO	NULL
BRL	NULL
)	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
complete	NULL
medium	NULL
for	NULL
one	NULL
additional	NULL
day	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
then	NULL
used	NULL
for	NULL
experiments	NULL
.	NULL

Subcellular	NULL
Fractionation	NULL
.	NULL

_	NULL
Nuclear	NULL
and	NULL
cytosolic	NULL
fractions	NULL
were	NULL
prepared	NULL
by	NULL
resuspending	NULL
cells	NULL
in	NULL
0.8	NULL
ml	NULL
ice	NULL
cold	NULL
buffer	NULL
A	NULL
(	NULL
250	NULL
mM	NULL
sucrose	NULL
,	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
,	NULL
1.5	NULL
mM	NULL
MgC	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
EGTA	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
17	NULL
pg/ml	NULL
phenyl-methylsulfonyl	NULL
fluoride	NULL
,	NULL
8	NULL
g/	NULL
ml	NULL
aprotinin	NULL
,	NULL
and	NULL
2	NULL
jug/	NULL
ml	NULL
leupep-tin	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
passed	NULL
through	NULL
an	NULL
ice	NULL
cold	NULL
cylindrical	NULL
cell	NULL
homogenizer	NULL
.	NULL

Cell	NULL
suspensions	NULL
were	NULL
pelleted	NULL
at	NULL
750	NULL
g	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Cytoplasmic	NULL
extract	NULL
was	NULL
separated	NULL
from	NULL
the	NULL
pellet	NULL
.	NULL

This	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
buffer	NULL
A	NULL
,	NULL
homogenized	NULL
,	NULL
and	NULL
spun	NULL
at	NULL
10,000	NULL
g	NULL
for	NULL
25	NULL
min	NULL
.	NULL

The	NULL
clear	NULL
supernatant	NULL
was	NULL
considered	NULL
nuclear	NULL
extract	NULL
.	NULL

Lysate	NULL
Preparation	NULL
.	NULL

-	NULL
For	NULL
Western	NULL
blot	NULL
analysis	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
10	NULL
mM	NULL
Tris	NULL
HCI	NULL
,	NULL
pH	NULL
7.6	NULL
;	NULL
150	NULL
mM	NULL
NaCl	NULL
;	NULL
0.5	NULL
mM	NULL
EDTA	NULL
;	NULL
1	NULL
mM	NULL
EGTA	NULL
;	NULL
1	NULL
%	NULL
SDS	NULL
;	NULL
1	NULL
mM	NULL
sodium	NULL
ortho-vanadate	NULL
;	NULL
and	NULL
a	NULL
mixture	NULL
of	NULL
protease	NULL
inhibitors	NULL
(	NULL
1	NULL
mM	NULL
phenyl-methylsulfonyl	NULL
fluoride	NULL
,	NULL
1	NULL
g/	NULL
ml	NULL
pepstatin	NULL
A	NULL
,	NULL
and	NULL
2	NULL
g/	NULL
ml	NULL
apro-tinin	NULL
}	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
then	NULL
sonicated	NULL
for	NULL
10	NULL
s	NULL
and	NULL
centrifuged	NULL
for	NULL
20	NULL
min	NULL
at	NULL
1,200	NULL
g.	NULL
The	NULL
supernatants	NULL
were	NULL
used	NULL
to	NULL
perform	NULL
SDS-PAGE	NULL
or	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Apoptosis	NULL
.	NULL

-	NULL
For	NULL
detection	NULL
of	NULL
apoptotic	NULL
cells	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
first	NULL
washed	NULL
twice	NULL
with	NULL
ice	NULL
cold	NULL
PBS	NULL
and	NULL
then	NULL
fixed	NULL
with	NULL
1	NULL
%	NULL
paraformaldehyde	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
fixed	NULL
cells	NULL
were	NULL
washed	NULL
again	NULL
with	NULL
PBS	NULL
and	NULL
stained	NULL
with	NULL
1	NULL
pg/ml	NULL
DAPI	NULL
solution	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
apoptotic	NULL
cells	NULL
were	NULL
examined	NULL
under	NULL
a	NULL
fluorescence	NULL
microscope	NULL
.	NULL

Fluorescent	NULL
nuclei	NULL
were	NULL
screened	NULL
for	NULL
normal	NULL
morphology	NULL
(	NULL
unal-tered	NULL
chromatin	NULL
)	NULL
,	NULL
and	NULL
apoptotic	NULL
nuclei	NULL
comprising	NULL
those	NULL
with	NULL
254	NULL
__	NULL
Inhibition	NULL
of	NULL
Fas	NULL
Ligand	NULL
Transcription	NULL
by	NULL
Bcl-2	NULL
fragmented	NULL
(	NULL
scattered	NULL
)	NULL
and	NULL
condensed	NULL
chromatin	NULL
were	NULL
counted	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
apoptotic	NULL
cells	NULL
in	NULL
total	NULL
counted	NULL
cells	NULL
.	NULL

Confoal	NULL
Microscopy	NULL
.	NULL

-	NULL
For	NULL
the	NULL
determination	NULL
of	NULL
NFAT	NULL
translocation	NULL
by	NULL
confocal	NULL
microscope	NULL
imaging	NULL
(	NULL
Axiovert	NULL
100	NULL
;	NULL
Carl	NULL
Zeiss	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
cells	NULL
from	NULL
each	NULL
group	NULL
were	NULL
seeded	NULL
onto	NULL
glass	NULL
slides	NULL
and	NULL
treated	NULL
with	NULL
paclitaxel	NULL
for	NULL
48	NULL
h.	NULL
At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
period	NULL
,	NULL
cells	NULL
were	NULL
fixed	NULL
with	NULL
1	NULL
%	NULL
paraformaldehyde	NULL
and	NULL
0.01	NULL
%	NULL
Triton	NULL
X-100	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
with	NULL
propidium	NULL
iodide	NULL
(	NULL
PI	NULL
;	NULL
2	NULL
g/ml	NULL
)	NULL
containing	NULL
RNAse	NULL
for	NULL
1	NULL
h	NULL
and	NULL
subsequently	NULL
with	NULL
anti-NFAT	NULL
antibody	NULL
(	NULL
goat	NULL
anti-human	NULL
IgG	NULL
;	NULL
2	NULL
pg/ml	NULL
)	NULL
for	NULL
1	NULL
h.	NULL
After	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
and	NULL
restained	NULL
with	NULL
secondary	NULL
antibody	NULL
(	NULL
donkey	NULL
anti-goat	NULL
IgG	NULL
)	NULL
conjugated	NULL
with	NULL
Alexa-488	NULL
for	NULL
1	NULL
h.	NULL
After	NULL
mounting	NULL
,	NULL
cells	NULL
were	NULL
visualized	NULL
for	NULL
NFAT	NULL
translocation	NULL
(	NULL
Alexa	NULL
;	NULL
emission	NULL
488	NULL
nm	NULL
and	NULL
excitation	NULL
520	NULL
nm	NULL
)	NULL
and	NULL
nuclear	NULL
fragmentation	NULL
(	NULL
PI	NULL
;	NULL
emission	NULL
540	NULL
nm	NULL
and	NULL
excitation	NULL
610	NULL
nm	NULL
)	NULL
.	NULL

The	NULL
green	NULL
and	NULL
red	NULL
colors	NULL
represent	NULL
cytoplasmic	NULL
NFAT	NULL
and	NULL
nuclear	NULL
staining	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
yellow	NULL
color	NULL
represents	NULL
NFAT	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
red	NULL
plus	NULL
green	NULL
)	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Results	NULL
FasL	NULL
Is	NULL
Involved	NULL
in	NULL
Poditaxel-induced	NULL
A	NULL
poptosis	NULL
:	NULL
-	NULL
FasL	NULL
induction	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
47-51	NULL
)	NULL
and	NULL
in	NULL
the	NULL
death	NULL
of	NULL
other	NULL
cell	NULL
types	NULL
induced	NULL
by	NULL
anticancer	NULL
drugs	NULL
(	NULL
52	NULL
)	NULL
,	NULL
gamma	NULL
irradiation	NULL
(	NULL
53	NULL
)	NULL
,	NULL
and	NULL
UV	NULL
light	NULL
(	NULL
54	NULL
)	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
possibility	NULL
of	NULL
the	NULL
involvement	NULL
of	NULL
the	NULL
FasL/	NULL
Fas	NULL
pathway	NULL
in	NULL
paclitaxel-	NULL
induced	NULL
apoptosis	NULL
.	NULL

Jurkat	NULL
cells	NULL
or	NULL
MDA-MB-231	NULL
cells	NULL
were	NULL
stably	NULL
transfected	NULL
with	NULL
either	NULL
pSSFV-Neo	NULL
or	NULL
pSSFV-Bcl-2	NULL
expression	NULL
vector	NULL
to	NULL
assess	NULL
the	NULL
protective	NULL
effects	NULL
of	NULL
Bel-2	NULL
on	NULL
paclitaxel-induced	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
paclitaxel	NULL
resulted	NULL
in	NULL
induction	NULL
of	NULL
apoptosis	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
,	NULL
and	NULL
overexpression	NULL
of	NULL
Bel-	NULL
2	NULL
inhibited	NULL
paclitaxel-	NULL
induced	NULL
apoptosis	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
.	NULL

The	NULL
paclitaxel	NULL
dose-response	NULL
curve	NULL
suggests	NULL
a	NULL
10-fold	NULL
increase	NULL
in	NULL
resistance	NULL
in	NULL
cells	NULL
overexpressing	NULL
Bcl-2	NULL
.	NULL

Neutralization	NULL
of	NULL
FasL	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
anti-FasL	NULL
antibody	NULL
(	NULL
NOK-2	NULL
)	NULL
significantly	NULL
inhibited	NULL
paclitaxel-induced	NULL
apoptosis	NULL
in	NULL
both	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/	NULL
Bcel-2	NULL
cells	NULL
.	NULL

Indeed	NULL
,	NULL
very	NULL
little	NULL
tumor	NULL
cell	NULL
death	NULL
could	NULL
be	NULL
documented	NULL
in	NULL
Bcel-2-over-expressing	NULL
Jurkat	NULL
cells	NULL
exposed	NULL
to	NULL
anti-FasL	NULL
antibody	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
role	NULL
of	NULL
Bel-2	NULL
in	NULL
paclitaxel-induced	NULL
apoptosis	NULL
,	NULL
we	NULL
used	NULL
MDA-MB-231	NULL
breast	NULL
cancer	NULL
cells	NULL
,	NULL
which	NULL
do	NULL
not	NULL
express	NULL
endogenous	NULL
Bcel-2	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

Overexpression	NULL
of	NULL
Bcl-2	NULL
in	NULL
MDA	NULL
cells	NULL
inhibited	NULL
paclitaxel-	NULL
induced	NULL
apoptosis	NULL
by	NULL
greater	NULL
than	NULL
two	NULL
logs	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
D	NULL
)	NULL
.	NULL

Neutralization	NULL
of	NULL
FasL	NULL
60	NULL
D	NULL
50	NULL
2	NULL
determinations	NULL
)	NULL
represent	NULL
one	NULL
of	NULL
three	NULL
separate	NULL
_	NULL
ca	NULL
C	NULL
--	NULL
O	NULL
--	NULL
MDA/Neo	NULL
3	NULL
4	NULL
==	NULL
--	NULL
JTNco	NULL
-e-	NULL
ha	NULL
»	NULL
Soar	NULL
wns	NULL
pag	NULL
ap	NULL
E	NULL
E	NULL
507	NULL
]	NULL
+	NULL
«	NULL
=*O	NULL
@	NULL
«	NULL
«	NULL
«	NULL
*	NULL
JT/Neo	NULL
+	NULL
anti-FasL	NULL
Ab	NULL
4Q	NULL
{	NULL
]	NULL
MBA/3532	NULL
f	NULL
anti-FasL	NULL
Ab	NULL
,	NULL
A	NULL
t	NULL
se=	NULL
<	NULL
&	NULL
r===	NULL
«	NULL
JT/Bcl-2	NULL
+	NULL
anti-FasL	NULL
Ab	NULL
'S	NULL
i	NULL
csemme	NULL
$	NULL
2	NULL
f	NULL
2	NULL
ey	NULL
2	NULL
.	NULL

2	NULL
.	NULL

3	NULL
#	NULL
4	NULL
o	NULL
2	NULL
207	NULL
3	NULL
3	NULL
2	NULL
.	NULL

2	NULL
.	NULL

&	NULL
S	NULL
<	NULL
<	NULL
a	NULL
o	NULL
o	NULL
o	NULL
B	NULL
Tks	NULL
X	NULL
~	NULL
av	NULL
33	NULL
0.001	NULL
0.01	NULL
0.1	NULL
``	NULL
0.001	NULL
0.01	NULL
0.1	NULL
EE	NULL
Paclitaxel	NULL
(	NULL
uM	NULL
)	NULL
E3	NULL
Paclitaxel	NULL
(	NULL
uM	NULL
)	NULL
a	NULL
23	NULL
EoS	NULL
F	NULL
50	NULL
mops	NULL
c	NULL
:	NULL
P	NULL
-B-	NULL
JT/Neo	NULL
O-	NULL
JTNeo	NULL
Figure	NULL
1	NULL
.	NULL

Bcl-2	NULL
inhibits	NULL
paclitaxel-induced	NULL
,	NULL
_|	NULL
mom	NULL
JTBc2	NULL
_	NULL
T	NULL
apoptosis	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
stably	NULL
transfected	NULL
.	NULL

*	NULL
«	NULL
~	NULL
@	NULL
****	NULL
JT/Neo	NULL
+	NULL
anti-Fas	NULL
Ab	NULL
49	NULL
]	NULL
-	NULL
JT/mut	NULL
CD95	NULL
with	NULL
cither	NULL
pSSFV-neo	NULL
or	NULL
pSFFV-Bcl-2	NULL
plas	NULL
g	NULL
ao	NULL
neent==	NULL
«	NULL
«	NULL
JT/Bcl-2	NULL
+	NULL
anti-Fas	NULL
Ab	NULL
ts	NULL
mid	NULL
.	NULL

(	NULL
B	NULL
)	NULL
MDA-MB-231	NULL
cells	NULL
were	NULL
stably	NULL
trans-2	NULL
|	NULL
3	NULL
fected	NULL
with	NULL
cither	NULL
pSSFV-neo	NULL
or	NULL
pSFFV-Bcl-2	NULL
S	NULL
f	NULL
)	NULL
30	NULL
-	NULL
plasmid	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Jurkat	NULL
cells	NULL
(	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/	NULL
Bcl-2	NULL
)	NULL
§	NULL
-	NULL
#	NULL
4	NULL
'S	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
0.001	NULL
,	NULL
0.01	NULL
,	NULL
and	NULL
E.	NULL
B	NULL
co	NULL
|	NULL
0.1	NULL
M	NULL
)	NULL
with	NULL
or	NULL
without	NULL
anti-FasL	NULL
neutralizing	NULL
&	NULL
»	NULL
4	NULL
2	NULL
.	NULL

_	NULL
antibody	NULL
(	NULL
NOK-2	NULL
;	NULL
1	NULL
ug/ml	NULL
!	NULL
)	NULL

for	NULL
48	NULL
h.	NULL
Cells	NULL
A	NULL
<	NULL
5	NULL
...	NULL
...	NULL
...	NULL
...	NULL
...	NULL
...	NULL
pd	NULL
were	NULL
stained	NULL
with	NULL
DAPI	NULL
and	NULL
visualized	NULL
under	NULL
5°	NULL
10	NULL
-	NULL
8°	NULL
ao	NULL
-	NULL
Pur	NULL
&	NULL
=	NULL
``	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

Cells	NULL
with	NULL
fragmented	NULL
nuclei	NULL
or	NULL
condensed	NULL
chromatin	NULL
were	NULL
counted	NULL
as	NULL
o	NULL
-|	NULL
o	NULL
_	NULL
“	NULL
|l	NULL
apoptotic	NULL
.	NULL

Data	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
of	NULL
quadruplicate	NULL
$	NULL
4	NULL
0.001	NULL
0.01	NULL
0.1	NULL
sé	NULL
“	NULL
0.001	NULL
.	NULL

Za	NULL
:	NULL
20	NULL
EE	NULL
Paclitaxel	NULL
(	NULL
uM	NULL
)	NULL
E3	NULL
G	NULL
E	NULL
Paclitaxel	NULL
(	NULL
uM	NULL
)	NULL
experiments	NULL
that	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

(	NULL
D	NULL
)	NULL
MDA/	NULL
MB/231	NULL
(	NULL
MDA/Nco	NULL
and	NULL
MDA/Bcl-2	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
0.001	NULL
,	NULL
0.01	NULL
,	NULL
and	NULL
0.1	NULL
M	NULL
)	NULL
with	NULL
or	NULL
without	NULL
anti-FasL	NULL
neutralizing	NULL
antibody	NULL
(	NULL
NOK-2	NULL
;	NULL
1	NULL
ug/ml	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Cells	NULL
were	NULL
stained	NULL
with	NULL
DAPI	NULL
and	NULL
visualized	NULL
under	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

Cells	NULL
with	NULL
fragmented	NULL
and	NULL
condensed	NULL
chromatin	NULL
were	NULL
counted	NULL
as	NULL
apoptotic	NULL
.	NULL

Data	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
of	NULL
quadruplicate	NULL
determinations	NULL
)	NULL
represent	NULL
one	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
that	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

(	NULL
E	NULL
)	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/	NULL
Bcel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
0.001	NULL
,	NULL
0.01	NULL
,	NULL
and	NULL
0.1	NULL
M	NULL
)	NULL
with	NULL
or	NULL
without	NULL
anti-Fas	NULL
blocking	NULL
antibody	NULL
(	NULL
1	NULL
g/	NULL
ml	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Apoptotic	NULL
nuclei	NULL
were	NULL
counted	NULL
as	NULL
described	NULL
for	NULL
D.	NULL
(	NULL
F	NULL
)	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/	NULL
mut	NULL
€D95	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
0.001	NULL
,	NULL
0.01	NULL
,	NULL
and	NULL
0.1	NULL
M	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Apoptotic	NULL
nuclei	NULL
were	NULL
counted	NULL
as	NULL
described	NULL
for	NULL
D.	NULL
255	NULL
-	NULL
Srivastava	NULL
et	NULL
al	NULL
.	NULL

by	NULL
anti-FasL	NULL
antibody	NULL
(	NULL
NOK-2	NULL
)	NULL
significantly	NULL
inhibited	NULL
paclitaxel-induced	NULL
apoptosis	NULL
in	NULL
MDA/	NULL
Neo	NULL
but	NULL
had	NULL
little	NULL
effect	NULL
in	NULL
MDA/	NULL
Bcl-2	NULL
cells	NULL
.	NULL

Incubation	NULL
of	NULL
cells	NULL
with	NULL
Fas-blocking	NULL
antibody	NULL
inhibited	NULL
paclitaxel-	NULL
induced	NULL
apoptosis	NULL
in	NULL
JT/Neo	NULL
and	NULL
JT/Bcel-2	NULL
cells	NULL
.	NULL

Similarly	NULL
,	NULL
overexpression	NULL
of	NULL
mutant	NULL
CD95/Fas	NULL
(	NULL
mutant	NULL
receptors	NULL
lacking	NULL
intracellular	NULL
cytoplasmic	NULL
domains	NULL
)	NULL
inhibited	NULL
paclitaxel-induced	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
F	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
demonstrate	NULL
that	NULL
(	NULL
a	NULL
)	NULL
paclitaxel-induced	NULL
apoptosis	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
Bcel-2	NULL
and	NULL
(	NULL
b	NULL
)	NULL
the	NULL
FasL/	NULL
Fas	NULL
pathway	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
mediates	NULL
paclitaxel-induced	NULL
apoptosis	NULL
.	NULL

Bd-2	NULL
Blocks	NULL
FasL	NULL
Expression	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
FasL	NULL
during	NULL
activation-	NULL
or	NULL
drug-induced	NULL
cell	NULL
death	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
47-52	NULL
)	NULL
.	NULL

As	NULL
neutralization	NULL
of	NULL
FasL	NULL
by	NULL
anti-FasL	NULL
antibody	NULL
inhibited	NULL
paclitaxel-induced	NULL
apoptosis	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
evaluate	NULL
the	NULL
expression	NULL
of	NULL
FasL	NULL
in	NULL
wild-type	NULL
and	NULL
Bcl-2-overexpressing	NULL
cells	NULL
.	NULL

Treatment	NULL
of	NULL
wild-type	NULL
MDA	NULL
cells	NULL
with	NULL
paclitaxel	NULL
,	NULL
vincristine	NULL
,	NULL
or	NULL
vinblastine	NULL
induced	NULL
FasL	NULL
expres	NULL
sion	NULL
in	NULL
a	NULL
time-dependent	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
breast	NULL
cancer	NULL
cells	NULL
(	NULL
MDA	NULL
and	NULL
MCF-7	NULL
)	NULL
with	NULL
paclitaxel	NULL
resulted	NULL
in	NULL
induction	NULL
of	NULL
FasL	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
Bel-	NULL
2	NULL
inhibits	NULL
apoptosis	NULL
induced	NULL
by	NULL
microtubule-damaging	NULL
drugs	NULL
(	NULL
paclitaxel	NULL
,	NULL
vincristine	NULL
,	NULL
and	NULL
vinblastine	NULL
)	NULL
(	NULL
25	NULL
)	NULL
;	NULL
therefore	NULL
,	NULL
it	NULL
was	NULL
of	NULL
interest	NULL
to	NULL
examine	NULL
whether	NULL
Bel-2	NULL
would	NULL
also	NULL
inhibit	NULL
FasL	NULL
expression	NULL
.	NULL

Treatment	NULL
of	NULL
MDA/	NULL
Neo	NULL
cells	NULL
with	NULL
50	NULL
nM	NULL
of	NULL
paclitaxel	NULL
or	NULL
vincristine	NULL
resulted	NULL
in	NULL
induction	NULL
of	NULL
FasL	NULL
;	NULL
by	NULL
contrast	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
FasL	NULL
was	NULL
blocked	NULL
by	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
in	NULL
MDA/Bcl-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
C	NULL
)	NULL
.	NULL

JT/Neo	NULL
cells	NULL
expressed	NULL
some	NULL
FasL	NULL
at	NULL
baseline	NULL
,	NULL
and	NULL
paclitaxel	NULL
induced	NULL
an	NULL
increase	NULL
in	NULL
FasL	NULL
expression	NULL
.	NULL

The	NULL
expres	NULL
sion	NULL
of	NULL
Bel-2	NULL
in	NULL
JT/	NULL
Bel-2	NULL
transfectants	NULL
blocked	NULL
both	NULL
the	NULL
baseline	NULL
expression	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
FasL	NULL
by	NULL
paclitaxel	NULL
MDA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
D	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
Bel-2	NULL
expression	NULL
interferes	NULL
with	NULL
FasL	NULL
expression	NULL
.	NULL

Bd-2	NULL
Blocks	NULL
NFAT	NULL
Translocation	NULL
to	NULL
the	NULL
Nudeus	NULL
.	NULL

-	NULL
The	NULL
activation	NULL
of	NULL
calcineurin	NULL
,	NULL
a	NULL
serine	NULL
phosphatase	NULL
,	NULL
is	NULL
regulated	NULL
by	NULL
calcium	NULL
.	NULL

Activated	NULL
calcineurin	NULL
functions	NULL
to	NULL
dephosphory-late	NULL
NFAT	NULL
family	NULL
members	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Dephosphorylated	NULL
NFAT	NULL
proteins	NULL
then	NULL
translocate	NULL
to	NULL
and	NULL
enter	NULL
the	NULL
nucleus	NULL
,	NULL
where	NULL
they	NULL
serve	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
regulating	NULL
the	NULL
expression	NULL
of	NULL
many	NULL
cytokine	NULL
genes	NULL
(	NULL
55	NULL
,	NULL
56	NULL
)	NULL
.	NULL

As	NULL
Bel-2	NULL
blocks	NULL
paclitaxel-induced	NULL
FasL	NULL
expression	NULL
and	NULL
apoptosis	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
Bel-2	NULL
on	NULL
NFAT	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

NFAT	NULL
was	NULL
localized	NULL
to	NULL
the	NULL
cytoplasm	NULL
in	NULL
untreated	NULL
(	NULL
control	NULL
)	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/	NULL
Bel-2	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

When	NULL
JT/	NULL
Neo	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
,	NULL
NFAT	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
overexpression	NULL
of	NULL
Bcl-2	NULL
blocked	NULL
paclitaxel-induced	NULL
NFAT	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
blocked	NULL
paclitaxel-induced	NULL
NFAT	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
in	NULL
MDA/	NULL
Bcl-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

We	NULL
confirmed	NULL
paclitaxel-induced	NULL
NFAT	NULL
translocation	NULL
by	NULL
confocal	NULL
microscopy	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
if	NULL
Bcl-2	NULL
would	NULL
block	NULL
NFAT	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
in	NULL
MDA	NULL
cells	NULL
by	NULL
immunocytochemistry	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
,	NULL
NFAT	NULL
was	NULL
localized	NULL
to	NULL
the	NULL
cytoplasm	NULL
in	NULL
MDA/Neo	NULL
and	NULL
MDA/	NULL
Bcl-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
green	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
MDA/Neo	NULL
cells	NULL
with	NULL
paclitaxel	NULL
resulted	NULL
in	NULL
NFAT	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
red	NULL
plus	NULL
green	NULL
=	NULL
yellow	NULL
color	NULL
)	NULL
and	NULL
apoptosis	NULL
(	NULL
frag-mented	NULL
nucleus	NULL
stained	NULL
with	NULL
red	NULL
color	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
blocked	NULL
paclitaxel-induced	NULL
NFAT	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
apoptosis	NULL
in	NULL
MDA	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Bd-2	NULL
Binds	NULL
to	NULL
Caldneurin	NULL
but	NULL
not	NULL
NFAT	NULL
.	NULL

-	NULL
The	NULL
Bcl-2	NULL
inhibition	NULL
of	NULL
NFAT	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
is	NULL
not	NULL
direct	NULL
but	NULL
rather	NULL
involves	NULL
calcineurin	NULL
(	NULL
57	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
MCF-7	NULL
A	NULL
B	NULL
24h	NULL
48	NULL
h	NULL
-	NULL
+	NULL
Vinblastine	NULL
o	NULL
+	NULL
+	NULL
-	NULL
Vincristine	NULL
Fo	NULL
-	NULL
+	NULL
--	NULL
Paclitaxel	NULL
-	NULL
e	NULL
«	NULL
«	NULL
**	NULL
/	NULL
FasL	NULL
sane	NULL
as	NULL
»	NULL
amp	NULL
asp	NULL
dib	NULL
an	NULL
am	NULL
am	NULL
B—AL	NULL
‘	NULL
U	NULL
]	NULL
!	NULL

MDA	NULL
C	NULL
D	NULL
MDA/Neo	NULL
:	NULL
MDA/Bcl-2	NULL
3	NULL
en	NULL
E-	NULL
3	NULL
EZ	NULL
]	NULL
3	NULL
C	NULL
3	NULL
0	NULL
E	NULL
0	NULL
T	NULL
5	NULL
a	NULL
dilittes	NULL
»	NULL
»	NULL
»	NULL
«	NULL
mme	NULL
:	NULL
FasL	NULL
aime	NULL
aime	NULL
«	NULL
iet	NULL
arh	NULL
oon	NULL
Ge	NULL
t	NULL
0.01	NULL
0.1	NULL
0	NULL
0.01	NULL
0.1	NULL
JT/Neo	NULL
-me	NULL
Paclitaxel	NULL
(	NULL
uM	NULL
)	NULL
w-	NULL
»	NULL
Coie	NULL
--	NULL
-	NULL
o	NULL
OW	NULL
casl	NULL
sities	NULL
commie	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
Bcl-2	NULL
inhibits	NULL
paclitaxel-	NULL
,	NULL
vincristine-	NULL
,	NULL
and	NULL
vinblastine-induced	NULL
FasL	NULL
expression	NULL
.	NULL

(	NULL
A	NULL
)	NULL
MDA	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
nM	NULL
of	NULL
paclitaxel	NULL
,	NULL
vincristine	NULL
,	NULL
or	NULL
vinblastine	NULL
for	NULL
either	NULL
24	NULL
or	NULL
48	NULL
h.	NULL
At	NULL
the	NULL
end	NULL
of	NULL
incubation	NULL
period	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
lysed	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
JT/Bcl-2	NULL
+	NULL
Paclitaxel	NULL
FasL	NULL
resolved	NULL
on	NULL
SDS-PAGE	NULL
.	NULL

FasL	NULL
levels	NULL
were	NULL
measured	NULL
by	NULL
Western	NULL
blot	NULL
anal-ammo	NULL
omi	NULL
.	NULL

sais	NULL
.	NULL

[	NULL
4	NULL
-iAC	NULL
(	NULL
i|	NULL
]	NULL
ysis	NULL
The	NULL
same	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
anti-B-actin	NULL
antibody	NULL
to	NULL
check	NULL
if	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
loaded	NULL
in	NULL
cach	NULL
lane	NULL
.	NULL

(	NULL
B	NULL
)	NULL
MDA	NULL
and	NULL
MCF-7	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
vari-	NULL
ous	NULL
concentrations	NULL
of	NULL
paclitaxel	NULL
for	NULL
48	NULL
h.	NULL
FasL	NULL
levels	NULL
were	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
anti-B-actin	NULL
antibody	NULL
to	NULL
check	NULL
if	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
loaded	NULL
in	NULL
cach	NULL
lane	NULL
.	NULL

(	NULL
C	NULL
)	NULL
MDA/	NULL
Neo	NULL
and	NULL
MDA/	NULL
Bel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
nM	NULL
of	NULL
paclitaxel	NULL
or	NULL
vincristine	NULL
for	NULL
48	NULL
h.	NULL
FasL	NULL
levels	NULL
were	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
anti-B-actin	NULL
antibody	NULL
to	NULL
check	NULL
if	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
loaded	NULL
in	NULL
cach	NULL
lane	NULL
.	NULL

(	NULL
D	NULL
)	NULL
JT/	NULL
Neo	NULL
and	NULL
JT	NULL
/	NULL
Bcl-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
FasL	NULL
levels	NULL
were	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
anti-B-actin	NULL
antibody	NULL
to	NULL
check	NULL
if	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
loaded	NULL
in	NULL
cach	NULL
lane	NULL
.	NULL

256	NULL
_	NULL
Inhibition	NULL
of	NULL
Fas	NULL
Ligand	NULL
Transcription	NULL
by	NULL
Bcl-2	NULL
B	NULL
JT/Neo	NULL
JT/Bcl-2	NULL
C	NULL
N	NULL
C	NULL
N	NULL
C	NULL
NFAT	NULL
mme	NULL
rane	NULL
:	NULL
Control	NULL
JT/Neo	NULL
C	NULL
N	NULL
JT/Bcl-2	NULL
C	NULL
N	NULL
NFAT	NULL
-	NULL
|	NULL
comme	NULL
.	NULL

comvenie	NULL
-	NULL
B-Actin	NULL
Paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
Bcl-2	NULL
binds	NULL
to	NULL
calcineurin	NULL
and	NULL
thereby	NULL
inhibits	NULL
translocation	NULL
of	NULL
NFAT	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
57	NULL
)	NULL
.	NULL

As	NULL
the	NULL
FasL	NULL
promoter	NULL
contains	NULL
NFAT	NULL
binding	NULL
sites	NULL
and	NULL
NFAT	NULL
participates	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
FasL	NULL
expression	NULL
in	NULL
activated	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
42	NULL
)	NULL
,	NULL
it	NULL
was	NULL
of	NULL
interest	NULL
to	NULL
examine	NULL
the	NULL
intracellular	NULL
mecha-nism	NULL
(	NULL
s	NULL
)	NULL
by	NULL
which	NULL
Bcel-2	NULL
inhibited	NULL
paclitaxel-induced	NULL
FasL	NULL
MDA/Neo	NULL
MDA/BcI2	NULL
Control	NULL
257	NULL
-	NULL
Srivastava	NULL
et	NULL
al	NULL
.	NULL

MDA/Neo	NULL
MDA/Neo	NULL
C	NULL
Paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
Paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
Figure	NULL
3	NULL
.	NULL

Bcl-2	NULL
blocks	NULL
NFAT	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

(	NULL
A	NULL
)	NULL
JT/Neo	NULL
and	NULL
JT/Bcl-2	NULL
cells	NULL
were	NULL
cither	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
or	NULL
vehicle	NULL
(	NULL
control	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Cells	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
cytoplasmic	NULL
(	NULL
C	NULL
)	NULL
and	NULL
nuclear	NULL
(	NULL
N	NULL
)	NULL
fractions	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Samples	NULL
were	NULL
resolved	NULL
on	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
anti-NFAT	NULL
antibody	NULL
.	NULL

The	NULL
same	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
anti-B-actin	NULL
antibody	NULL
.	NULL

(	NULL
B	NULL
)	NULL
MDA/Nco	NULL
and	NULL
MDA/Bcl-2	NULL
cells	NULL
were	NULL
either	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
or	NULL
vehicle	NULL
for	NULL
48	NULL
h.	NULL
Cells	NULL
were	NULL
harvested	NULL
and	NULL
C	NULL
and	NULL
N	NULL
fractions	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Samples	NULL
were	NULL
rc-solved	NULL
on	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
anti-NFAT	NULL
antibody	NULL
.	NULL

The	NULL
same	NULL
blot	NULL
was	NULL
reprobed	NULL
.	NULL

with	NULL
anti-B-actin	NULL
antibody	NULL
.	NULL

MDA/BcI-2	NULL
N	NULL
C	NULL
N	NULL
NFAT	NULL
~ammecmune	NULL
B-Actin	NULL
Control	NULL
MDA/BcI-2	NULL
N	NULL
C	NULL
N	NULL
NFAT	NULL
B-Actin	NULL
expression	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
microtubule-damaging	NULL
drugs	NULL
initiated	NULL
a	NULL
signaling	NULL
cascade	NULL
that	NULL
phosphorylated	NULL
Bel-2	NULL
in	NULL
a	NULL
time-	NULL
and	NULL
dose-dependent	NULL
manner	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
JT/	NULL
Neo	NULL
and	NULL
JT	NULL
/	NULL
Bcel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
nM	NULL
of	NULL
either	NULL
paclitaxel	NULL
or	NULL
vincristine	NULL
for	NULL
24	NULL
h	NULL
,	NULL
lysed	NULL
,	NULL
immunoprecipitated	NULL
with	NULL
anti-	NULL
NFAT	NULL
antibody	NULL
,	NULL
and	NULL
blotted	NULL
Figure	NULL
4	NULL
.	NULL

Confocal	NULL
microscopy	NULL
showing	NULL
blockage	NULL
of	NULL
NFAT	NULL
translocation	NULL
by	NULL
Bcl-2	NULL
.	NULL

MDA/Neo	NULL
and	NULL
MDA/Bcl-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Cells	NULL
were	NULL
fixed	NULL
and	NULL
stained	NULL
with	NULL
anti-	NULL
NFAT	NULL
antibody	NULL
along	NULL
with	NULL
PI	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
and	NULL
restained	NULL
with	NULL
secondary	NULL
antibody	NULL
conjugated	NULL
with	NULL
Alexa-488	NULL
.	NULL

Green	NULL
and	NULL
red	NULL
represent	NULL
cytoplasmic	NULL
NFAT	NULL
and	NULL
nuclear	NULL
staining	NULL
,	NULL
respectively	NULL
.	NULL

Yellow	NULL
,	NULL
NFAT	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

with	NULL
anti-Bcl-2	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicated	NULL
that	NULL
NFAT	NULL
did	NULL
not	NULL
bind	NULL
to	NULL
Bel-2	NULL
in	NULL
either	NULL
JT/Neo	NULL
or	NULL
JT/Bcel-2	NULL
cells	NULL
When	NULL
the	NULL
NFAT	NULL
immunoprecipitate	NULL
was	NULL
followed	NULL
by	NULL
NFAT	NULL
Western	NULL
blot	NULL
,	NULL
similar	NULL
amounts	NULL
of	NULL
NFAT	NULL
were	NULL
immunoprecipitated	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
apparent	NULL
lack	NULL
of	NULL
association	NULL
of	NULL
NFAT	NULL
and	NULL
Bel-2	NULL
is	NULL
not	NULL
related	NULL
to	NULL
inefficient	NULL
NFAT	NULL
immunoprecipitation	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
interaction	NULL
between	NULL
Bel-2	NULL
and	NULL
calcineurin	NULL
in	NULL
paclitaxel-	NULL
or	NULL
vincristine-treated	NULL
JT/Neo	NULL
and	NULL
JT/Bcl-2	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
exposed	NULL
to	NULL
paclitaxel	NULL
or	NULL
vincristine	NULL
for	NULL
48	NULL
h	NULL
and	NULL
then	NULL
lysed	NULL
.	NULL

Lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
antibody	NULL
to	NULL
either	NULL
Bel-2	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
)	NULL
or	NULL
calcineurin	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
C	NULL
)	NULL
,	NULL
and	NULL
Western	NULL
blots	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
antibody	NULL
not	NULL
used	NULL
in	NULL
the	NULL
immunoprecipitation	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
and	NULL
C	NULL
,	NULL
Bel-2	NULL
was	NULL
able	NULL
to	NULL
bind	NULL
calcineurin	NULL
in	NULL
untreated	NULL
JT/	NULL
Neo	NULL
and	NULL
JT	NULL
/	NULL
Bel-2	NULL
cells	NULL
.	NULL

When	NULL
JT/	NULL
Neo	NULL
and	NULL
JT	NULL
/	NULL
Bel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
or	NULL
vincristine	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
,	NULL
less	NULL
calcineurin	NULL
was	NULL
bound	NULL
to	NULL
Bcel-2	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
Bcel-2	NULL
binds	NULL
to	NULL
calcineurin	NULL
but	NULL
not	NULL
to	NULL
NFAT	NULL
,	NULL
and	NULL
the	NULL
fraction	NULL
of	NULL
Bcel-2	NULL
and	NULL
calcineurin	NULL
bound	NULL
to	NULL
each	NULL
other	NULL
decreases	NULL
upon	NULL
exposure	NULL
to	NULL
the	NULL
drugs	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
phosphorylation	NULL
of	NULL
Bcel-2	NULL
stimulated	NULL
by	NULL
the	NULL
drugs	NULL
may	NULL
also	NULL
influence	NULL
Bcl-2	NULL
binding	NULL
to	NULL
calcineurin	NULL
just	NULL
as	NULL
it	NULL
affects	NULL
Bel-2-Bax	NULL
interaction	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
immunosuppressants	NULL
cyclosporin	NULL
and	NULL
FK506	NULL
inhibit	NULL
NFAT	NULL
-dependent	NULL
transcriptional	NULL
events	NULL
by	NULL
binding	NULL
calcineurin	NULL
and	NULL
blocking	NULL
its	NULL
enzymatic	NULL
activity	NULL
,	NULL
thus	NULL
preventing	NULL
the	NULL
redistribution	NULL
of	NULL
NFAT	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
36	NULL
)	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
involvement	NULL
of	NULL
active	NULL
calcineurin	NULL
in	NULL
paclitaxel-induced	NULL
apoptosis	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
FK506	NULL
analogue	NULL
ascomycin	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
D	NULL
)	NULL
.	NULL

Paclitaxel	NULL
induced	NULL
apoptosis	NULL
in	NULL
both	NULL
JT/	NULL
Neo	NULL
and	NULL
MDA/	NULL
Neo	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
D	NULL
)	NULL
.	NULL

If	NULL
Bel-2	NULL
A	NULL
B	NULL
IT/Neo	NULL
JT/Bcl-2	NULL
y	NULL
JT/Neo	NULL
JT/Bcl-2	NULL
+	NULL
+	NULL
Vincristine	NULL
<	NULL
+	NULL
+	NULL
-	NULL
Paclitaxel	NULL
s	NULL
+	NULL
Vincristine	NULL
IP	NULL
:	NULL
Anti	NULL
-Bcl-2	NULL
o	NULL
*	NULL
*	NULL
Paclitaxel	NULL
wite	NULL
--	NULL
@	NULL
the	NULL
m	NULL
--	NULL
»	NULL
Calcineurin	NULL
[	NULL
P	NULL
;	NULL
NF-AT	NULL
mie	NULL
Bcl-2	NULL
«	NULL
ams	NULL
aam	NULL
«	NULL
mme	NULL
«	NULL
te	NULL
somme	NULL
came	NULL
SVAT	NULL
C	NULL
JT/Neo	NULL
JT/Bcl-2	NULL
-	NULL
+	NULL
-	NULL
+	NULL
Vincristine	NULL
+	NULL
-	NULL
+	NULL
-	NULL
Paclitaxel	NULL
IP	NULL
:	NULL
Anti-Calcineurin	NULL
P	NULL
mma	NULL
-	NULL
Bel-2	NULL
D	NULL
E	NULL
60	NULL
60	NULL
ggerz	NULL
emule	NULL
-	NULL
MDA/Nc0	NULL
JT/Neo	NULL
FT/Neo	NULL
+	NULL
Ascomycin	NULL
.	NULL

+	NULL
Ascomycin	NULL
g	NULL
503	NULL
]	NULL
m	NULL
@	NULL
®	NULL
az	NULL
JT/Bel-2	NULL
+	NULL
Ascomycin	NULL
lg	NULL
a=	NULL
4	NULL
@	NULL
p	NULL
=	NULL
=~	NULL
.	NULL

MDA/Bcl-2	NULL
+	NULL
Ascomycin	NULL
E	NULL
«	NULL
»	NULL
«	NULL
@	NULL
...	NULL
.	NULL

JT/Neo	NULL
+	NULL
BAPTA	NULL
F	NULL
,	NULL
40	NULL
-|	NULL
«	NULL
=enggyes	NULL
»	NULL
JTBcl-2	NULL
+	NULL
BAPTA	NULL
é	NULL
40	NULL
<	NULL
&	NULL
40	NULL
-	NULL
9	NULL
2	NULL
.	NULL

3	NULL
S	NULL
30-€	NULL
30-	NULL
8	NULL
30	NULL
-	NULL
g	NULL
8	NULL
&	NULL
20	NULL
a	NULL
&	NULL
<	NULL
-5	NULL
&	NULL
20	NULL
{	NULL
-A	NULL
«	NULL
20	NULL
4	NULL
®	NULL
10-	NULL
nne	NULL
``	NULL
S	NULL
<	NULL
gﬁﬁ	NULL
``	NULL
—-	NULL
-	NULL
&	NULL
e	NULL
16h..	NULL
--	NULL
.°..mna	NULL
®	NULL
104	NULL
“	NULL
yum	NULL
``	NULL
.	NULL

a	NULL
10	NULL
<	NULL
0	NULL
T	NULL
t	NULL
-r	NULL
y	NULL
0	NULL
0.001	NULL
0.01	NULL
0.1	NULL
0480	NULL
-	NULL
,	NULL
r	NULL
r	NULL
_	NULL
,	NULL
r	NULL
r	NULL
Paclitaxel	NULL
(	NULL
uM	NULL
)	NULL
$	NULL
30001	NULL
-	NULL
o01	NULL
0.1	NULL
£5	NULL
0.001	NULL
0.01	NULL
o.1	NULL
EE	NULL
Paclitaxel	NULL
(	NULL
uM	NULL
)	NULL
Ep	NULL
Paclitaxel	NULL
(	NULL
uM	NULL
)	NULL
Figure	NULL
5	NULL
.	NULL

-	NULL
Bcl-2	NULL
binds	NULL
to	NULL
calcineurin	NULL
but	NULL
not	NULL
NFAT	NULL
.	NULL

(	NULL
A	NULL
)	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/	NULL
Bel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
nM	NULL
of	NULL
paclitaxel	NULL
or	NULL
vincristine	NULL
for	NULL
48	NULL
h.	NULL
The	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
10	NULL
jg	NULL
of	NULL
anti-	NULL
NFAT	NULL
antibody	NULL
and	NULL
20	NULL
wl	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
resolved	NULL
on	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
either	NULL
anti-Bel-2	NULL
antibody	NULL
(	NULL
top	NULL
pane	NULL
!	NULL
)	NULL

or	NULL
anti-NF-AT	NULL
antibody	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/Bel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
nM	NULL
of	NULL
paclitaxel	NULL
or	NULL
vincristine	NULL
for	NULL
48	NULL
h.	NULL
The	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
10	NULL
jug	NULL
of	NULL
anti-Bel-2	NULL
antibody	NULL
and	NULL
20	NULL
pl	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
resolved	NULL
on	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
anticalcineurin	NULL
.	NULL

(	NULL
C	NULL
)	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/	NULL
Bcl-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
nM	NULL
of	NULL
paclitaxel	NULL
or	NULL
vincristine	NULL
for	NULL
48	NULL
h.	NULL
The	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
10	NULL
wg	NULL
of	NULL
anticalcineurin	NULL
antibody	NULL
and	NULL
20	NULL
jul	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
resolved	NULL
on	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
anti-Bcl-2	NULL
antibody	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Left	NULL
,	NULL
JT/	NULL
Neo	NULL
and	NULL
JT	NULL
/	NULL
Bel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
paclitaxel	NULL
(	NULL
0.001	NULL
,	NULL
0.01	NULL
,	NULL
and	NULL
0.1	NULL
M	NULL
)	NULL
with	NULL
or	NULL
without	NULL
FK506	NULL
analogue	NULL
ascomycin	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
for	NULL
48	NULL
h	NULL
to	NULL
measure	NULL
apoptosis	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
DAPI	NULL
and	NULL
visualized	NULL
under	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

Cells	NULL
with	NULL
fragmented	NULL
nuclei	NULL
or	NULL
condensed	NULL
chromatin	NULL
were	NULL
counted	NULL
as	NULL
apoptotic	NULL
.	NULL

Data	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
of	NULL
quadruplicate	NULL
determinations	NULL
)	NULL
represent	NULL
one	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
that	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

Right	NULL
,	NULL
MDA/	NULL
Neo	NULL
and	NULL
MDA/	NULL
Bel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
paclitaxel	NULL
(	NULL
0.001	NULL
,	NULL
0.01	NULL
,	NULL
and	NULL
0.1	NULL
M	NULL
)	NULL
with	NULL
or	NULL
without	NULL
FK506	NULL
analogue	NULL
ascomycin	NULL
(	NULL
10	NULL
M	NULL
)	NULL
for	NULL
48	NULL
h	NULL
to	NULL
measure	NULL
apoptosis	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
DAPI	NULL
and	NULL
visualized	NULL
under	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

Data	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
of	NULL
quadruplicate	NULL
determinations	NULL
)	NULL
represent	NULL
one	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
that	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

(	NULL
E	NULL
)	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/	NULL
Bel-2	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
[	NULL
(	NULL
Ca	NULL
``	NULL
*	NULL
)	NULL
i	NULL
]	NULL
chelator	NULL
BAPTA-AM	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
for	NULL
45	NULL
min	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
for	NULL
48	NULL
h	NULL
to	NULL
measure	NULL
apoptosis	NULL
Data	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
of	NULL
quadruplicate	NULL
determinations	NULL
)	NULL
represent	NULL
one	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
that	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

258	NULL
-	NULL
Inhibition	NULL
of	NULL
Fas	NULL
Ligand	NULL
Transcription	NULL
by	NULL
Bcl-2	NULL
was	NULL
acting	NULL
to	NULL
prevent	NULL
calcineurin	NULL
activation	NULL
,	NULL
its	NULL
effects	NULL
should	NULL
have	NULL
been	NULL
mimicked	NULL
by	NULL
the	NULL
pharmacological	NULL
calcineurin	NULL
inhibition	NULL
of	NULL
ascomycin	NULL
.	NULL

Overexpression	NULL
of	NULL
Bel-2	NULL
inhibited	NULL
paclitaxel-induced	NULL
apoptosis	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
ascomycin	NULL
inhibited	NULL
paclitaxel-induced	NULL
apoptosis	NULL
in	NULL
neo-	NULL
and	NULL
Bel-2-transfected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
D	NULL
)	NULL
.	NULL

Ascomycin	NULL
appears	NULL
to	NULL
inhibit	NULL
apoptosis	NULL
ad-ditively	NULL
in	NULL
Bcel-2-expressing	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
ascomycin	NULL
has	NULL
additional	NULL
effects	NULL
unrelated	NULL
to	NULL
Bcl-2	NULL
binding	NULL
of	NULL
calcineurin	NULL
.	NULL

These	NULL
data	NULL
confirm	NULL
that	NULL
inhibition	NULL
of	NULL
calcineurin	NULL
activation	NULL
blocks	NULL
paclitaxel-induced	NULL
apoptosis	NULL
.	NULL

Because	NULL
a	NULL
rise	NULL
in	NULL
intracellular	NULL
free	NULL
calcium	NULL
levels	NULL
[	NULL
(	NULL
C	NULL
#	NULL
+*	NULL
)	NULL
i	NULL
]	NULL
is	NULL
essential	NULL
for	NULL
calcineurin	NULL
activation	NULL
(	NULL
56	NULL
)	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
chelating	NULL
intracellular	NULL
free	NULL
calcium	NULL
by	NULL
BAPTA-AM	NULL
on	NULL
paclitaxel-induced	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
E	NULL
)	NULL
.	NULL

JT/Neo	NULL
and	NULL
JT/Bcel-2	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
10	NULL
uM	NULL
BAPT	NULL
A-AM	NULL
for	NULL
45	NULL
min	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Overexpression	NULL
of	NULL
Bel-2	NULL
significantly	NULL
inhibited	NULL
paclitaxel-induced	NULL
apoptosis	NULL
.	NULL

Interestingly	NULL
,	NULL
chelation	NULL
of	NULL
intracellular	NULL
free	NULL
calcium	NULL
by	NULL
BAPT	NULL
A-AM	NULL
inhibited	NULL
paclitaxel	NULL
induced	NULL
apoptosis	NULL
in	NULL
JT/	NULL
Neo	NULL
and	NULL
JT	NULL
/	NULL
Bel-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
E	NULL
)	NULL
.	NULL

That	NULL
paclitaxel	NULL
induces	NULL
a	NULL
rise	NULL
in	NULL
[	NULL
(	NULL
C	NULL
#	NULL
+*	NULL
)	NULL
i	NULL
]	NULL
has	NULL
been	NULL
described	NULL
by	NULL
others	NULL
(	NULL
58	NULL
)	NULL
and	NULL
confirmed	NULL
by	NULL
us	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
a	NULL
rise	NULL
in	NULL
is	NULL
required	NULL
for	NULL
paclitaxel-induced	NULL
apoptosis	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
additional	NULL
evidence	NULL
that	NULL
paclitaxel-induced	NULL
apoptosis	NULL
involves	NULL
a	NULL
rise	NULL
in	NULL
[	NULL
(	NULL
C	NULL
#	NULL
+*	NULL
)	NULL
i	NULL
]	NULL
,	NULL
leading	NULL
to	NULL
calcineurin	NULL
activation	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
leads	NULL
to	NULL
NFAT	NULL
translocation	NULL
and	NULL
expression	NULL
of	NULL
FasL	NULL
.	NULL

BH4	NULL
Domain	NULL
of	NULL
Bd-2	NULL
Is	NULL
Required	NULL
for	NULL
Interaction	NULL
with	NULL
Cal-aneurin	NULL
and	NULL
Paditaxel-induced	NULL
FasL	NULL
Expression	NULL
and	NULL
Apoptosis	NULL
.	NULL

Thus	NULL
,	NULL
Bcel-2	NULL
blocked	NULL
NFAT	NULL
translocation	NULL
by	NULL
binding	NULL
to	NULL
calcineurin	NULL
but	NULL
not	NULL
directly	NULL
to	NULL
NFAT	NULL
.	NULL

The	NULL
BH4	NULL
domain	NULL
of	NULL
Bcl-2	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
mediate	NULL
heterodimerization	NULL
with	NULL
calcineurin	NULL
.	NULL

We	NULL
wished	NULL
to	NULL
use	NULL
this	NULL
finding	NULL
to	NULL
verify	NULL
that	NULL
the	NULL
antiapoptotic	NULL
effects	NULL
of	NULL
Bel-2	NULL
were	NULL
related	NULL
to	NULL
calcineurin	NULL
binding	NULL
.	NULL

To	NULL
answer	NULL
this	NULL
question	NULL
,	NULL
MDA	NULL
cells	NULL
were	NULL
trans	NULL
fected	NULL
with	NULL
empty	NULL
vector	NULL
(	NULL
MDA/Neo	NULL
)	NULL
,	NULL
wild-type	NULL
Bcl-2	NULL
(	NULL
MDA/Bcel-2	NULL
)	NULL
,	NULL
or	NULL
ABH4	NULL
Bcel-2	NULL
(	NULL
Bcel-2	NULL
lacking	NULL
ABH4	NULL
do-main	NULL
,	NULL
MDA/ABH4	NULL
Bcel-2	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
A	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
or	NULL
left	NULL
untreated	NULL
(	NULL
control	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
)	NULL
.	NULL

x	NULL
5:2	NULL
)	NULL
a	NULL
8	NULL
0	NULL
S	NULL
&	NULL
``	NULL
C	NULL
S	NULL
``	NULL
[	NULL
@	NULL
``	NULL
$	NULL
0	NULL
©	NULL
)	NULL
A	NULL
mmm	NULL
»	NULL
A.	NULL
w*	NULL
-	NULL
>	NULL
E	NULL
50	NULL
T_	NULL
--	NULL
MDaNc	NULL
~-~aABH4	NULL
Bcl-2	NULL
2	NULL
<	NULL
<	NULL
|e	NULL
&	NULL
...	NULL
...	NULL
MDA/ABH4	NULL
Bcl-2	NULL
%	NULL
407	NULL
«	NULL
-	NULL
«	NULL
.	NULL

«	NULL
G	NULL
@	NULL
--	NULL
-	NULL
MDA/Bcl-2	NULL
2	NULL
====g	NULL
@	NULL
r==*	NULL
MDA/AIoop	NULL
Bcl-2	NULL
MDA/Neo	NULL
MDA/ABH4	NULL
Bcl-2	NULL
MDA/Bcl-2	NULL
g	NULL
304	NULL
&	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
Paclitaxel	NULL
3	NULL
B	NULL
@	NULL
,	NULL
20-®	NULL
10-	NULL
.	NULL

o	NULL
c	NULL
e	NULL
..	NULL
sona	NULL
~A	NULL
~8	NULL
0	NULL
m	NULL
r	NULL
r	NULL
r	NULL
0	NULL
0.001	NULL
0.01	NULL
0.1	NULL
MDA/Neo	NULL
MDA/Bcl-2	NULL
-	NULL
MDA/ABH4	NULL
Bcl-2	NULL
Paclitaxel	NULL
(	NULL
uM	NULL
)	NULL
~	NULL
+	NULL
~	NULL
+	NULL
~	NULL
+	NULL
FSLQMCI	NULL
Icineuri	NULL
Figure	NULL
6	NULL
.	NULL

-	NULL
Bcl-2	NULL
interacts	NULL
with	NULL
calcineurin	NULL
through	NULL
its	NULL
BH4	NULL
C	NULL
BLjLzml-c	NULL
'd	NULL
cineurin	NULL
domain	NULL
in	NULL
inhibiting	NULL
paclitaxel-induced	NULL
FasL	NULL
expression	NULL
and	NULL
apoptosis	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Western	NULL
blot	NULL
showing	NULL
overexpressed	NULL
wild-type	NULL
Bcl-2	NULL
and	NULL
ABH4	NULL
Bcl-2	NULL
in	NULL
MDA-MB-231	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
MDA/	NULL
MDA/Neo	NULL
MDAMIoop	NULL
Bcl-2	NULL
-	NULL
MDA/Bcl-2	NULL
Neo	NULL
,	NULL
MDA/ABH4	NULL
Bcl-2	NULL
,	NULL
and	NULL
MDA/Bcl-2	NULL
cells	NULL
were	NULL
.	NULL

treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Cells	NULL
were	NULL
harvested	NULL
+	NULL
~	NULL
+	NULL
~	NULL
+	NULL
_	NULL
Paclitaxel	NULL
and	NULL
lysed	NULL
.	NULL

FasL	NULL
expression	NULL
was	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
anal-D	NULL
L	NULL
ysis	NULL
.	NULL

The	NULL
same	NULL
blot	NULL
was	NULL
reprobed	NULL
with	NULL
anti-B-actin	NULL
antibody	NULL
.	NULL

ammo	NULL
Bol-2	NULL
(	NULL
C	NULL
)	NULL
MDA/	NULL
Neo	NULL
,	NULL
MDA/	NULL
Bcl-2	NULL
,	NULL
and	NULL
MDA/	NULL
ABH4	NULL
Bel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
The	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
10	NULL
jug	NULL
of	NULL
anti-	NULL
«	NULL
mime	NULL
Aloop	NULL
Bcel-2	NULL
calcineurin	NULL
antibody	NULL
and	NULL
20	NULL
pul	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
resolved	NULL
on	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
anti-Bcl-2	NULL
antibody	NULL
.	NULL

(	NULL
D	NULL
)	NULL
MDA/Neo	NULL
,	NULL
MDA/Aloop	NULL
MDA/Neo	NULL
_	NULL
loop	NULL
Bcl-2	NULL
_	NULL
MDA/Bcl-2	NULL
Bcl-2	NULL
,	NULL
and	NULL
MDA/Bcl-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
R	NULL
+	NULL
R	NULL
+	NULL
R	NULL
+	NULL
Paclitaxel	NULL
(	NULL
200	NULL
nM	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Top	NULL
panclzcell	NULL
1y§atcs	NULL
were	NULL
run	NULL
on	NULL
SDS-IP	NULL
:	NULL
Anti-Bel-2	NULL
PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
anti-Bcl-2	NULL
antibody	NULL
.	NULL

Bot-m	NULL
e	NULL
--	NULL
»	NULL
Calcineurin	NULL
tom	NULL
panel	NULL
,	NULL
cell	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti	NULL
Bcl-2	NULL
antibody	NULL
,	NULL
run	NULL
on	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
immunoblotted	NULL
with	NULL
anticalcineurin	NULL
antibody	NULL
.	NULL

(	NULL
E	NULL
)	NULL
MDA/	NULL
Neo	NULL
,	NULL
MDA/	NULL
ABH4	NULL
Bcl-2	NULL
,	NULL
MDA/Aloop	NULL
Bcl-2	NULL
,	NULL
and	NULL
MDA/Bcl-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
0.001	NULL
,	NULL
0.01	NULL
,	NULL
and	NULL
0.1	NULL
wM	NULL
)	NULL
for	NULL
48	NULL
h	NULL
to	NULL
measure	NULL
apoptosis	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
DAPI	NULL
and	NULL
visualized	NULL
under	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

Data	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
of	NULL
quadruplicate	NULL
determinations	NULL
)	NULL
represent	NULL
one	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
that	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

259	NULL
-	NULL
Srivastava	NULL
et	NULL
al	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
B	NULL
demonstrates	NULL
that	NULL
paclitaxel	NULL
induced	NULL
FasL	NULL
expression	NULL
in	NULL
MDA/Neo	NULL
cells	NULL
Overexpression	NULL
of	NULL
wild-type	NULL
Bcl-2	NULL
(	NULL
MDA/Bcel-2	NULL
)	NULL
,	NULL
but	NULL
not	NULL
ABH4	NULL
Bcl-2	NULL
,	NULL
inhibited	NULL
paclitaxel-induced	NULL
FasL	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
)	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
ABH4	NULL
Bcl-2	NULL
to	NULL
bind	NULL
with	NULL
calcineurin	NULL
in	NULL
MDA	NULL
cells	NULL
MDA/	NULL
neo	NULL
,	NULL
MDA/	NULL
Bel-2	NULL
,	NULL
and	NULL
MDA/	NULL
ABH4	NULL
Bel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
paclitaxel	NULL
,	NULL
and	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anticalcineurin	NULL
antibody	NULL
and	NULL
immunoblotted	NULL
with	NULL
anti-Bcl-2	NULL
antibody	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
C	NULL
demonstrates	NULL
that	NULL
wild-type	NULL
Bcl-2	NULL
can	NULL
be	NULL
coimmunoprecipitated	NULL
with	NULL
calcineurin	NULL
,	NULL
and	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
low	NULL
doses	NULL
of	NULL
paclitaxel	NULL
significantly	NULL
inhibited	NULL
the	NULL
Bcl-2-calcineurin	NULL
interaction	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
ABH4	NULL
Bcl-2	NULL
was	NULL
unable	NULL
to	NULL
heterodimerize	NULL
with	NULL
calcineurin	NULL
.	NULL

As	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
paclitaxel	NULL
causes	NULL
more	NULL
complete	NULL
Bel-2	NULL
phosphorylation	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
examine	NULL
if	NULL
phosphorylated	NULL
Bcl-2	NULL
can	NULL
bind	NULL
to	NULL
calcineurin	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
loop	NULL
region	NULL
of	NULL
Bcl-2	NULL
is	NULL
an	NULL
important	NULL
target	NULL
for	NULL
regulatory	NULL
phosphorylation	NULL
(	NULL
59	NULL
,	NULL
60	NULL
)	NULL
.	NULL

MDA/	NULL
Neo	NULL
,	NULL
MDA/	NULL
Aloop	NULL
Bel-2	NULL
(	NULL
which	NULL
can	NULL
not	NULL
be	NULL
phosphorylated	NULL
)	NULL
,	NULL
and	NULL
MDA/Bcel-2	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
200	NULL
nM	NULL
paclitaxel	NULL
for	NULL
48	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
D	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
MDA/	NULL
Bcel-2	NULL
cells	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
paclitaxel	NULL
causes	NULL
phos	NULL
phorylation	NULL
of	NULL
wild-type	NULL
Bcel-2	NULL
,	NULL
whereas	NULL
paclitaxel	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
Aloop	NULL
Bel-2	NULL
(	NULL
phosphorylation-deficient	NULL
mutant	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
D	NULL
,	NULL
top	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
phosphorylated	NULL
Bel-2	NULL
was	NULL
unable	NULL
to	NULL
bind	NULL
with	NULL
calcineurin	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
D	NULL
,	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

By	NULL
comparison	NULL
,	NULL
Aloop	NULL
Bel-2	NULL
was	NULL
not	NULL
phosphorylated	NULL
by	NULL
paclitaxel	NULL
and	NULL
formed	NULL
heterodimers	NULL
with	NULL
calcineurin	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
phosphorylation	NULL
of	NULL
Bel-2	NULL
is	NULL
essential	NULL
for	NULL
calcineurin	NULL
to	NULL
be	NULL
released	NULL
from	NULL
the	NULL
complex	NULL
.	NULL

Because	NULL
ABH4	NULL
Bcl-2	NULL
was	NULL
not	NULL
able	NULL
to	NULL
bind	NULL
with	NULL
calcineurin	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
this	NULL
mutant	NULL
on	NULL
paclitaxel-induced	NULL
apoptosis	NULL
Overexpression	NULL
of	NULL
wild-type	NULL
Bcel-2	NULL
in	NULL
MDA	NULL
cells	NULL
significantly	NULL
inhibited	NULL
paclitaxel	NULL
A	NULL
14000	NULL
L_	NULL
]	NULL
Control	NULL
B	NULL
RRB	NULL
Paclitaxel	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
12000-10000	NULL
8000-1	NULL
6000	NULL
4000-	NULL
Relative	NULL
Light	NULL
Units	NULL
2000	NULL
0	NULL
.	NULL

-	NULL
w	NULL
3	NULL
5	NULL
C	NULL
3	NULL
1	NULL
%	NULL
S	NULL
3	NULL
$	NULL
s	NULL
£00	NULL
go	NULL
2	NULL
50	NULL
go	NULL
g	NULL
€	NULL
§	NULL
i000	NULL
460	NULL
f	NULL
f	NULL
a	NULL
a	NULL
)	NULL
A	NULL
2	NULL
”	NULL
,	NULL
U	NULL
o	NULL
Z.	NULL
JT/Neo	NULL
JT/Bcl-2	NULL
induced	NULL
apoptosis	NULL
,	NULL
whereas	NULL
overexpression	NULL
of	NULL
ABH4	NULL
Bel-2	NULL
mutant	NULL
had	NULL
only	NULL
a	NULL
slight	NULL
inhibiting	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
E	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
overexpression	NULL
of	NULL
Aloop	NULL
Bel-2	NULL
completely	NULL
inhibited	NULL
paclitaxel-induced	NULL
apoptosis	NULL
Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
ABH4	NULL
domain	NULL
of	NULL
Bel-2	NULL
plays	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
heterodimerizing	NULL
with	NULL
calcineurin	NULL
and	NULL
inhibiting	NULL
paclitaxel-induced	NULL
apoptosis	NULL
,	NULL
and	NULL
the	NULL
phosphorylation	NULL
of	NULL
the	NULL
Bcel-2	NULL
loop	NULL
domain	NULL
allosterically	NULL
interferes	NULL
with	NULL
the	NULL
BH4-calcineurin	NULL
interaction	NULL
.	NULL

Bd-2	NULL
Blocks	NULL
Paditaxel-induced	NULL
FasL	NULL
Promoter	NULL
A	NULL
divity	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
FasL	NULL
promoter	NULL
contains	NULL
two	NULL
NFAT	NULL
binding	NULL
sites	NULL
(	NULL
42	NULL
,	NULL
43	NULL
)	NULL
.	NULL

We	NULL
next	NULL
addressed	NULL
the	NULL
functional	NULL
importance	NULL
of	NULL
the	NULL
two	NULL
NFAT	NULL
sites	NULL
for	NULL
paclitaxel-	NULL
mediated	NULL
FasL	NULL
expression	NULL
by	NULL
generating	NULL
mutations	NULL
at	NULL
one	NULL
or	NULL
both	NULL
NFAT	NULL
binding	NULL
sites	NULL
.	NULL

Two	NULL
FasL	NULL
sites	NULL
were	NULL
also	NULL
mutated	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
full	NULL
length	NULL
,	NULL
486-bp	NULL
FasL	NULL
reporter	NULL
so	NULL
that	NULL
FasL	NULL
expression	NULL
in	NULL
this	NULL
system	NULL
would	NULL
not	NULL
kill	NULL
the	NULL
cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
reporter	NULL
or	NULL
double	NULL
mutant	NULL
reporter	NULL
constructs	NULL
and	NULL
then	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
paclitaxel	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
A	NULL
,	NULL
treatment	NULL
of	NULL
JT/	NULL
Neo	NULL
cells	NULL
transfected	NULL
with	NULL
wild-type	NULL
FasL	NULL
reporter	NULL
resulted	NULL
in	NULL
a	NULL
10-fold	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
relative	NULL
to	NULL
control	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
reporter	NULL
containing	NULL
mutations	NULL
in	NULL
both	NULL
NFAT	NULL
sites	NULL
exhibited	NULL
no	NULL
luciferase	NULL
production	NULL
over	NULL
control	NULL
in	NULL
JT/	NULL
Neo	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
A	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
overexpression	NULL
of	NULL
the	NULL
Bel-2	NULL
gene	NULL
in	NULL
JT	NULL
cells	NULL
(	NULL
JT/	NULL
Bcl-2	NULL
)	NULL
inhibited	NULL
wild-type	NULL
FasL	NULL
promoter	NULL
activity	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
paclitaxel	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
low	NULL
levels	NULL
of	NULL
luciferase	NULL
activity	NULL
were	NULL
detected	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
double	NULL
NFAT	NULL
mutant	NULL
reporter	NULL
plasmid	NULL
in	NULL
JT	NULL
/	NULL
Bel-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
A	NULL
)	NULL
.	NULL

We	NULL
next	NULL
sought	NULL
to	NULL
examine	NULL
the	NULL
FasL	NULL
promoter	NULL
activation	NULL
in	NULL
MDA-MB-231	NULL
cells	NULL
that	NULL
do	NULL
not	NULL
express	NULL
endogenous	NULL
Bcl-2	NULL
protein	NULL
.	NULL

Paclitaxel	NULL
treatment	NULL
of	NULL
MDA/	NULL
Neo	NULL
cells	NULL
transfected	NULL
with	NULL
wild-type	NULL
FasL	NULL
reporter	NULL
resulted	NULL
in	NULL
a	NULL
12-fold	NULL
increase	NULL
in	NULL
12000	NULL
[	NULL
-	NULL
]	NULL
Control	NULL
10000	NULL
-|	NULL
M	NULL
@	NULL
Paclitaxel	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
m	NULL
42	NULL
'	NULL
2	NULL
8000-7	NULL
-3	NULL
42	NULL
G	NULL
,	NULL
sooo	NULL
<	NULL
S	NULL
$	NULL
4000-43	NULL
-S	NULL
&	NULL
20007	NULL
o-	NULL
S	NULL
2	NULL
S	NULL
Pa	NULL
\	NULL
3	NULL
&	NULL
E	NULL
3	NULL
2	NULL
so	NULL
3	NULL
&	NULL
3	NULL
.	NULL
}	NULL

f	NULL
ps	NULL
=	NULL
23	NULL
o	NULL
E	NULL
al	NULL
3	NULL
2	NULL
P	NULL
C	NULL
£	NULL
I	NULL
=	NULL
£0	NULL
A	NULL
f	NULL
T	NULL
A	NULL
2	NULL
>	NULL
&	NULL
A	NULL
7	NULL
U	NULL
A	NULL
MDA/Neo	NULL
MDA/Bcl-2	NULL
Figure	NULL
7	NULL
.	NULL

-	NULL
NFAT	NULL
sites	NULL
play	NULL
important	NULL
roles	NULL
in	NULL
FasL	NULL
promoter	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
(	NULL
JT/	NULL
Neo	NULL
and	NULL
JT/	NULL
Bel-2	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
70	NULL
ug	NULL
of	NULL
the	NULL
wild-type	NULL
486-bp	NULL
FasL	NULL
reporter	NULL
(	NULL
FasL-486	NULL
)	NULL
or	NULL
a	NULL
reporter	NULL
containing	NULL
mutations	NULL
in	NULL
both	NULL
the	NULL
distal	NULL
and	NULL
proximal	NULL
NFAT	NULL
sites	NULL
(	NULL
double	NULL
mutant	NULL
)	NULL
.	NULL

Transfectants	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
control	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Cells	NULL
were	NULL
lysed	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
arbitrary	NULL
luciferase	NULL
light	NULL
units	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

Error	NULL
bars	NULL
,	NULL
SE	NULL
of	NULL
triplicate	NULL
samples	NULL
.	NULL

(	NULL
B	NULL
)	NULL
MDA/	NULL
Neo	NULL
and	NULL
MDA/	NULL
Bel-2	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
70	NULL
jug	NULL
of	NULL
the	NULL
wild-type	NULL
486-bp	NULL
FasL	NULL
reporter	NULL
(	NULL
FasL-486	NULL
)	NULL
or	NULL
a	NULL
reporter	NULL
containing	NULL
mutations	NULL
in	NULL
both	NULL
the	NULL
distal	NULL
and	NULL
proximal	NULL
NFAT	NULL
sites	NULL
(	NULL
double	NULL
mutant	NULL
)	NULL
.	NULL

Transfectants	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
control	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
paclitaxel	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Cells	NULL
were	NULL
lysed	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
arbitrary	NULL
luciferase	NULL
light	NULL
units	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

Error	NULL
bars	NULL
,	NULL
SE	NULL
of	NULL
triplicate	NULL
samples	NULL
.	NULL

260	NULL
Inhibition	NULL
of	NULL
Fas	NULL
Ligand	NULL
Transcription	NULL
by	NULL
Bel-2	NULL
luciferase	NULL
activity	NULL
relative	NULL
to	NULL
control	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
blocked	NULL
FasL	NULL
promoter	NULL
activation	NULL
in	NULL
pacli-taxel-treated	NULL
MDA/	NULL
Bel-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
B	NULL
)	NULL
.	NULL

By	NULL
comparison	NULL
,	NULL
low	NULL
levels	NULL
of	NULL
luciferase	NULL
activity	NULL
were	NULL
detected	NULL
in	NULL
cells	NULL
trans	NULL
fected	NULL
with	NULL
double	NULL
NFAT	NULL
mutant	NULL
reporter	NULL
plasmid	NULL
in	NULL
MDA/	NULL
Bcel-2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
A	NULL
)	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
Bcl-2	NULL
blocked	NULL
FasL	NULL
transcription	NULL
by	NULL
inhibiting	NULL
NFAT	NULL
activity	NULL
.	NULL

Discussion	NULL
Involvement	NULL
of	NULL
FasL	NULL
in	NULL
Apoptosis	NULL
.	NULL

-	NULL
Activation	NULL
of	NULL
T	NULL
cells	NULL
results	NULL
in	NULL
expression	NULL
of	NULL
FasL	NULL
and	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL

In	NULL
comparison	NULL
to	NULL
activation-induced	NULL
FasL	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
FasL	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
other	NULL
selected	NULL
cell	NULL
types	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
FasL	NULL
expression	NULL
on	NULL
cells	NULL
in	NULL
immune	NULL
privileged	NULL
sites	NULL
,	NULL
such	NULL
as	NULL
testis	NULL
(	NULL
9	NULL
)	NULL
and	NULL
the	NULL
anterior	NULL
chamber	NULL
of	NULL
the	NULL
eye	NULL
(	NULL
10	NULL
)	NULL
,	NULL
has	NULL
suggested	NULL
that	NULL
FasL	NULL
may	NULL
be	NULL
important	NULL
in	NULL
tolerance	NULL
induction	NULL
and	NULL
immunosuppression	NULL
.	NULL

Indeed	NULL
,	NULL
inflammatory	NULL
cells	NULL
in	NULL
the	NULL
anterior	NULL
chamber	NULL
of	NULL
the	NULL
eye	NULL
undergo	NULL
Fas	NULL
mediated	NULL
apoptosis	NULL
and	NULL
show	NULL
a	NULL
systemic	NULL
tolerance	NULL
to	NULL
herpes	NULL
simplex	NULL
virus	NULL
(	NULL
HSV-1	NULL
)	NULL
infection	NULL
(	NULL
10	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
immune	NULL
cells	NULL
,	NULL
expression	NULL
of	NULL
FasL	NULL
on	NULL
human	NULL
tumors	NULL
,	NULL
including	NULL
colon	NULL
(	NULL
61	NULL
)	NULL
,	NULL
hepatocellular	NULL
carcinoma	NULL
(	NULL
62	NULL
,	NULL
63	NULL
)	NULL
,	NULL
melanoma	NULL
(	NULL
12	NULL
)	NULL
,	NULL
and	NULL
lung	NULL
carcinoma	NULL
(	NULL
13	NULL
)	NULL
has	NULL
been	NULL
demonstrated	NULL
;	NULL
this	NULL
expression	NULL
on	NULL
cancer	NULL
cells	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
induction	NULL
of	NULL
apoptosis	NULL
in	NULL
Fas-expressing	NULL
T	NULL
cells	NULL
.	NULL

Here	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
paclitaxel-induced	NULL
apoptosis	NULL
in	NULL
lymphoid	NULL
and	NULL
breast	NULL
tumor	NULL
cells	NULL
is	NULL
mediated	NULL
at	NULL
least	NULL
in	NULL
part	NULL
by	NULL
increased	NULL
expression	NULL
of	NULL
FasL	NULL
.	NULL

As	NULL
Fas	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
most	NULL
tumors	NULL
cells	NULL
,	NULL
induction	NULL
of	NULL
FasL	NULL
would	NULL
be	NULL
an	NULL
amplification	NULL
signal	NULL
for	NULL
tumor	NULL
cell	NULL
apoptosis	NULL
.	NULL

FasL-neutralizing	NULL
antibody	NULL
nearly	NULL
completely	NULL
abrogates	NULL
apoptosis	NULL
induced	NULL
by	NULL
microtubule	NULL
poisons	NULL
such	NULL
as	NULL
paclitaxel	NULL
and	NULL
vinblastine	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
environmental	NULL
stress	NULL
mediated	NULL
by	NULL
exposure	NULL
to	NULL
gamma	NULL
irradiation	NULL
(	NULL
53	NULL
)	NULL
,	NULL
UV	NULL
light	NULL
(	NULL
54	NULL
)	NULL
,	NULL
and	NULL
anticancer	NULL
drugs	NULL
such	NULL
as	NULL
etoposide	NULL
or	NULL
doxorubicin	NULL
(	NULL
52	NULL
)	NULL
induces	NULL
upregulation	NULL
of	NULL
Fas	NULL
receptors	NULL
and	NULL
ligands	NULL
,	NULL
resulting	NULL
in	NULL
autocrine	NULL
or	NULL
paracrine	NULL
cell	NULL
death	NULL
.	NULL

However	NULL
,	NULL
the	NULL
level	NULL
of	NULL
Fas	NULL
expression	NULL
is	NULL
only	NULL
one	NULL
of	NULL
the	NULL
factors	NULL
regulating	NULL
the	NULL
susceptibility	NULL
to	NULL
Fas	NULL
mediated	NULL
apoptosis	NULL
(	NULL
64	NULL
)	NULL
.	NULL

Exposure	NULL
to	NULL
radiation	NULL
,	NULL
anticancer	NULL
drugs	NULL
,	NULL
or	NULL
other	NULL
forms	NULL
of	NULL
stress	NULL
may	NULL
lead	NULL
to	NULL
apoptosis	NULL
,	NULL
not	NULL
only	NULL
by	NULL
increasing	NULL
surface	NULL
expression	NULL
of	NULL
Fas	NULL
,	NULL
but	NULL
also	NULL
by	NULL
affecting	NULL
intracellular	NULL
signaling	NULL
molecules	NULL
activated	NULL
upon	NULL
Fas	NULL
ligation	NULL
.	NULL

Indeed	NULL
,	NULL
numerous	NULL
drug-resis	NULL
tant	NULL
cell	NULL
lines	NULL
were	NULL
also	NULL
found	NULL
to	NULL
be	NULL
resistant	NULL
to	NULL
Fas-	NULL
mediated	NULL
apoptosis	NULL
(	NULL
65	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
support	NULL
the	NULL
hypothesis	NULL
that	NULL
apoptosis	NULL
mediated	NULL
by	NULL
both	NULL
chemotherapeutic	NULL
agents	NULL
and	NULL
physiologic	NULL
stimuli	NULL
such	NULL
as	NULL
Fas	NULL
ligation	NULL
may	NULL
share	NULL
common	NULL
downstream	NULL
effector	NULL
molecules	NULL
.	NULL

Bd-2	NULL
Inhibits	NULL
N	NULL
FAT	NULL
Translocation	NULL
to	NULL
the	NULL
N	NULL
udeus	NULL
by	NULL
Binding	NULL
to	NULL
Calaneunin	NULL
but	NULL
not	NULL
NFAT	NULL
.	NULL

-	NULL
The	NULL
expression	NULL
of	NULL
FasL	NULL
is	NULL
inhibited	NULL
by	NULL
immunosuppressive	NULL
agents	NULL
CsA	NULL
and	NULL
FK506	NULL
(	NULL
47	NULL
,	NULL
50	NULL
,	NULL
66	NULL
,	NULL
67	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT	NULL
is	NULL
involved	NULL
in	NULL
FasL	NULL
induction	NULL
.	NULL

Our	NULL
data	NULL
demonstrate	NULL
that	NULL
the	NULL
FK506	NULL
analogue	NULL
ascomycin	NULL
inhibits	NULL
paclitaxel-induced	NULL
FasL	NULL
expression	NULL
and	NULL
blocks	NULL
apoptosis	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
calcineurin-NFAT	NULL
pathway	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
FasL	NULL
expression	NULL
and	NULL
consequent	NULL
paclitaxel-	NULL
induced	NULL
apoptosis	NULL
.	NULL

261	NULL
Srivastava	NULL
et	NULL
al	NULL
.	NULL

Current	NULL
evidence	NULL
indicates	NULL
that	NULL
both	NULL
nuclear	NULL
import	NULL
and	NULL
export	NULL
of	NULL
NFAT	NULL
can	NULL
be	NULL
regulated	NULL
dynamically	NULL
(	NULL
68	NULL
,	NULL
69	NULL
)	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
relatively	NULL
profound	NULL
and	NULL
sustained	NULL
cytosolic	NULL
C	NULL
#	NULL
+	NULL
transients	NULL
,	NULL
such	NULL
as	NULL
those	NULL
that	NULL
occur	NULL
after	NULL
antigen	NULL
receptor	NULL
engagement	NULL
,	NULL
appear	NULL
to	NULL
be	NULL
necessary	NULL
to	NULL
activate	NULL
calcineurin	NULL
and	NULL
counterbalance	NULL
the	NULL
effects	NULL
of	NULL
processes	NULL
that	NULL
effect	NULL
nuclear	NULL
export	NULL
of	NULL
NFAT	NULL
(	NULL
70	NULL
)	NULL
.	NULL

It	NULL
has	NULL
recently	NULL
been	NULL
suggested	NULL
that	NULL
the	NULL
Ca	NULL
#	NULL
*	NULL
signals	NULL
of	NULL
shorter	NULL
duration	NULL
elicited	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
Ga	NULL
,	NULL
receptors	NULL
may	NULL
preferentially	NULL
activate	NULL
the	NULL
putative	NULL
negative	NULL
regulatory	NULL
processes	NULL
(	NULL
71	NULL
)	NULL
,	NULL
whereas	NULL
activation	NULL
of	NULL
calcineurin	NULL
,	NULL
dephosphorylation	NULL
of	NULL
NFAT	NULL
,	NULL
and	NULL
its	NULL
subsequent	NULL
nuclear	NULL
import	NULL
require	NULL
Ca*	NULL
transients	NULL
of	NULL
longer	NULL
duration	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
provided	NULL
evidence	NULL
that	NULL
a	NULL
nuclear	NULL
kinase	NULL
activity	NULL
is	NULL
involved	NULL
in	NULL
rephosphorylating	NULL
NFAT	NULL
and	NULL
exporting	NULL
it	NULL
to	NULL
the	NULL
cytosol	NULL
as	NULL
a	NULL
means	NULL
for	NULL
terminating	NULL
its	NULL
transcriptional	NULL
activity	NULL
(	NULL
72	NULL
)	NULL
.	NULL

Although	NULL
protein	NULL
kinase	NULL
A	NULL
and	NULL
glycogen	NULL
synthase	NULL
kinase	NULL
3	NULL
have	NULL
been	NULL
implicated	NULL
as	NULL
the	NULL
major	NULL
NFAT	NULL
kinases	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
calmodulin-depen-dent	NULL
kinases	NULL
appear	NULL
to	NULL
have	NULL
some	NULL
NFAT	NULL
nuclear	NULL
export	NULL
activity	NULL
as	NULL
well	NULL
as	NULL
a	NULL
heterotopic	NULL
expression	NULL
system	NULL
(	NULL
70	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
NFAT	NULL
regulates	NULL
the	NULL
induction	NULL
of	NULL
FasL	NULL
upon	NULL
paclitaxel	NULL
treatment	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
breast	NULL
cancer	NULL
cells	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
the	NULL
FasL	NULL
promoter	NULL
contains	NULL
two	NULL
NFAT	NULL
binding	NULL
sites	NULL
(	NULL
bp	NULL
-263	NULL
to	NULL
-283	NULL
relative	NULL
to	NULL
the	NULL
FasL	NULL
translation	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
a	NULL
mutation	NULL
in	NULL
this	NULL
NFAT	NULL
site	NULL
(	NULL
within	NULL
the	NULL
context	NULL
of	NULL
a	NULL
486-bp	NULL
FasL	NULL
reporter	NULL
)	NULL
to	NULL
prevent	NULL
reporter	NULL
activity	NULL
in	NULL
lymphocytes	NULL
illustrates	NULL
that	NULL
this	NULL
response	NULL
element	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
regulated	NULL
expression	NULL
of	NULL
FasL	NULL
in	NULL
our	NULL
studies	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
observation	NULL
that	NULL
CsA	NULL
inhibits	NULL
expression	NULL
of	NULL
FasL	NULL
(	NULL
47	NULL
,	NULL
50	NULL
,	NULL
67	NULL
)	NULL
in	NULL
lymphocytes	NULL
and	NULL
that	NULL
NFAT	NULL
-deficient	NULL
mice	NULL
do	NULL
not	NULL
inducibly	NULL
express	NULL
FasL	NULL
(	NULL
73	NULL
)	NULL
,	NULL
these	NULL
results	NULL
strongly	NULL
suggest	NULL
that	NULL
NFAT	NULL
transcription	NULL
factors	NULL
are	NULL
critical	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
FasL	NULL
expression	NULL
in	NULL
lymphocytes	NULL
and	NULL
breast	NULL
carcinoma	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
FasL	NULL
reporter	NULL
expression	NULL
is	NULL
blocked	NULL
by	NULL
overexpression	NULL
of	NULL
Bcl-2	NULL
.	NULL

The	NULL
comparison	NULL
of	NULL
the	NULL
NFAT	NULL
binding	NULL
region	NULL
of	NULL
the	NULL
FasL	NULL
promoter	NULL
with	NULL
IL-2	NULL
and	NULL
TNF-a	NULL
promoters	NULL
provides	NULL
some	NULL
insight	NULL
into	NULL
the	NULL
regulation	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

AP-1	NULL
(	NULL
acti-vator	NULL
protein	NULL
1	NULL
)	NULL
binding	NULL
sequences	NULL
are	NULL
adjacent	NULL
to	NULL
NFAT	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
74	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
NFAT	NULL
sites	NULL
from	NULL
the	NULL
FasL	NULL
promoter	NULL
do	NULL
not	NULL
include	NULL
any	NULL
surrounding	NULL
predicted	NULL
AP-1	NULL
binding	NULL
sequences	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
FasL	NULL
promoter	NULL
NFAT	NULL
binding	NULL
site	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
a	NULL
previously	NULL
reported	NULL
NFAT	NULL
site	NULL
within	NULL
the	NULL
TNF-a	NULL
promoter	NULL
(	NULL
75	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
structural	NULL
and	NULL
functional	NULL
similarities	NULL
between	NULL
TNF-a	NULL
and	NULL
FasL	NULL
,	NULL
it	NULL
is	NULL
intriguing	NULL
to	NULL
speculate	NULL
that	NULL
the	NULL
conserved	NULL
NFAT	NULL
regulatory	NULL
sequences	NULL
within	NULL
the	NULL
promoters	NULL
of	NULL
these	NULL
genes	NULL
may	NULL
have	NULL
arisen	NULL
from	NULL
a	NULL
common	NULL
ancestral	NULL
apoptosis-inducing	NULL
gene	NULL
.	NULL

As	NULL
FasL	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
control	NULL
of	NULL
lymphocyte	NULL
apoptosis	NULL
,	NULL
and	NULL
,	NULL
according	NULL
to	NULL
our	NULL
data	NULL
,	NULL
drug-induced	NULL
apoptosis	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
the	NULL
intracellular	NULL
mechanism	NULL
of	NULL
FasL	NULL
induction	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
and	NULL
breast	NULL
cancer	NULL
cells	NULL
The	NULL
mechanism	NULL
by	NULL
which	NULL
Bel-2	NULL
inhibits	NULL
drug-induced	NULL
FasL	NULL
expression	NULL
and	NULL
apoptosis	NULL
is	NULL
not	NULL
known	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
that	NULL
Bcel-2	NULL
inhibits	NULL
paclitaxel-induced	NULL
NFAT	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
through	NULL
interactions	NULL
with	NULL
calcineurin	NULL
.	NULL

In	NULL
deed	NULL
,	NULL
Bel-2	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
NFAT	NULL
directly	NULL
,	NULL
as	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
by	NULL
others	NULL
(	NULL
57	NULL
)	NULL
.	NULL

The	NULL
BH4	NULL
domain	NULL
of	NULL
Bel-2	NULL
binds	NULL
to	NULL
calcineurin	NULL
and	NULL
thereby	NULL
inhibits	NULL
the	NULL
translocation	NULL
of	NULL
NFAT	NULL
.	NULL

Calcium-dependent	NULL
phosphorylation	NULL
of	NULL
calcineurin	NULL
is	NULL
essential	NULL
for	NULL
activation	NULL
of	NULL
NFAT	NULL
and	NULL
subsequent	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
paclitaxel-induced	NULL
NFAT	NULL
translocation	NULL
and	NULL
apoptosis	NULL
by	NULL
Bcl-2	NULL
may	NULL
be	NULL
one	NULL
of	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
Bel-2	NULL
regulates	NULL
apoptosis	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
microtubule-damaging	NULL
drugs	NULL
(	NULL
paclitaxel	NULL
,	NULL
vincristine	NULL
,	NULL
and	NULL
vinblastine	NULL
)	NULL
induced	NULL
Bel-2	NULL
phosphorylation	NULL
and	NULL
apoptosis	NULL
.	NULL

Indeed	NULL
,	NULL
phosphorylated	NULL
Bel-2	NULL
loses	NULL
its	NULL
antiapoptotic	NULL
function	NULL
and	NULL
is	NULL
unable	NULL
to	NULL
heterodimerize	NULL
with	NULL
the	NULL
proapoptotic	NULL
partner	NULL
Bax	NULL
.	NULL

This	NULL
free	NULL
Bax	NULL
itself	NULL
can	NULL
induce	NULL
apoptosis	NULL
.	NULL

Therefore	NULL
,	NULL
phosphorylation	NULL
of	NULL
Bcel-2	NULL
may	NULL
result	NULL
in	NULL
at	NULL
least	NULL
two	NULL
events	NULL
:	NULL
(	NULL
a	NULL
)	NULL
release	NULL
of	NULL
Bax	NULL
and	NULL
(	NULL
b	NULL
)	NULL
failure	NULL
to	NULL
hold	NULL
on	NULL
to	NULL
or	NULL
sequester	NULL
calcineurin	NULL
.	NULL

Model	NULL
:	NULL
Inhibition	NULL
of	NULL
Paditaxel-induced	NULL
Apoptosis	NULL
by	NULL
Bd-2	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
data	NULL
support	NULL
a	NULL
model	NULL
in	NULL
which	NULL
microtubule-damaging	NULL
drugs	NULL
such	NULL
as	NULL
paclitaxel	NULL
stimulate	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
free	NULL
C	NULL
#	NULL
+	NULL
that	NULL
activates	NULL
calcineurin	NULL
,	NULL
which	NULL
results	NULL
in	NULL
NFAT	NULL
nuclear	NULL
translocation	NULL
,	NULL
FasL	NULL
expression	NULL
,	NULL
and	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
A	NULL
)	NULL
.	NULL

Apoptosis	NULL
can	NULL
be	NULL
blocked	NULL
either	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
anti-FasL	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
or	NULL
by	NULL
overexpression	NULL
of	NULL
Bel-2	NULL
.	NULL

Bel-2	NULL
sequesters	NULL
calcineurin	NULL
,	NULL
which	NULL
results	NULL
in	NULL
blockage	NULL
of	NULL
NFAT	NULL
nuclear	NULL
translocation	NULL
,	NULL
FasL	NULL
expression	NULL
,	NULL
and	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
B	NULL
)	NULL
.	NULL

All	NULL
of	NULL
the	NULL
phosphorylation	NULL
sites	NULL
of	NULL
Bel-2	NULL
are	NULL
located	NULL
within	NULL
the	NULL
loop	NULL
region	NULL
(	NULL
amino	NULL
acid	NULL
32-80	NULL
)	NULL
.	NULL

The	NULL
loop	NULL
region	NULL
deletion	NULL
mutant	NULL
Bcl-2	NULL
(	NULL
Aloop	NULL
Bel-2	NULL
)	NULL
can	NULL
not	NULL
be	NULL
phosphorylated	NULL
and	NULL
does	NULL
not	NULL
release	NULL
calcineurin	NULL
from	NULL
the	NULL
complex	NULL
after	NULL
paclitaxel	NULL
exposure	NULL
,	NULL
and	NULL
it	NULL
becomes	NULL
hyperfunctional	NULL
in	NULL
inhibiting	NULL
drug-induced	NULL
apoptosis	NULL
The	NULL
inhibition	NULL
of	NULL
FasL	NULL
translocation	NULL
by	NULL
Bel-2	NULL
can	NULL
be	NULL
overcome	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
paclitaxel	NULL
(	NULL
>	NULL
100	NULL
nM	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
C	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
paclitaxel	NULL
results	NULL
in	NULL
inactivation	NULL
of	NULL
Bcel-2	NULL
through	NULL
phosphorylation	NULL
.	NULL

Phosphorylated	NULL
Bel-2	NULL
can	NULL
not	NULL
bind	NULL
calcineurin	NULL
,	NULL
and	NULL
NFAT	NULL
activation	NULL
and	NULL
FasL	NULL
expression	NULL
can	NULL
occur	NULL
after	NULL
Bel-2	NULL
phosphorylation	NULL
.	NULL

Nucleus	NULL
p__	NULL
A	NULL
®	NULL
--	NULL
-	NULL
»	NULL
-b	NULL
_	NULL
--	NULL
p	NULL
OMG	NULL
NFAT	NULL
Nuclear	NULL
pore	NULL
No	NULL
Bcl-2	NULL
Fas	NULL
ligand	NULL
Apoptosis	NULL
Nucleus	NULL
Unphosphorylated	NULL
Bcl-2	NULL
X	NULL
No	NULL
Fas	NULL
ligand	NULL
No	NULL
Apoptosis	NULL
Nucleus	NULL
OKO	NULL
c	NULL
Gomme	NULL
)	NULL
--	NULL
»	NULL
-	NULL
>	NULL
--	NULL
»	NULL
@	NULL
)	NULL
NFAT	NULL
Nuclear	NULL
pore	NULL
Qﬁ	NULL
Fas	NULL
ligand	NULL
L	NULL
Phosphorylated	NULL
Bcl-2	NULL
Apoptosis	NULL
Figure	NULL
8	NULL
.	NULL

-	NULL
Model	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
NFAT	NULL
signaling	NULL
by	NULL
Bcl-2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Treatment	NULL
of	NULL
cells	NULL
with	NULL
paclitaxel	NULL
results	NULL
in	NULL
calcineurin	NULL
activation	NULL
,	NULL
NFAT	NULL
nuclear	NULL
translocation	NULL
,	NULL
FasL	NULL
expression	NULL
,	NULL
and	NULL
apoptosis	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Unphosphorylated	NULL
Bel-2	NULL
binds	NULL
to	NULL
calcineurin	NULL
and	NULL
blocks	NULL
NFAT	NULL
nuclear	NULL
translocation	NULL
,	NULL
FasL	NULL
expression	NULL
,	NULL
and	NULL
apoptosis	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Phosphorylation	NULL
of	NULL
Bel-2	NULL
results	NULL
in	NULL
release	NULL
of	NULL
calcineurin	NULL
from	NULL
the	NULL
complex	NULL
,	NULL
translocation	NULL
of	NULL
NFAT	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
and	NULL
induction	NULL
of	NULL
FasL	NULL
expression	NULL
and	NULL
apoptosis	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
Charles	NULL
Filburn	NULL
for	NULL
assisting	NULL
us	NULL
with	NULL
confocal	NULL
microscopy	NULL
work	NULL
.	NULL

We	NULL
also	NULL
extend	NULL
our	NULL
sincere	NULL
thanks	NULL
to	NULL
Dr.	NULL
Stanley	NULL
J.	NULL
Korsmeyer	NULL
(	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
for	NULL
providing	NULL
the	NULL
Bel-2	NULL
expression	NULL
vector	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
Gary	NULL
Koretzky	NULL
(	NULL
University	NULL
of	NULL
Iowa	NULL
,	NULL
Iowa	NULL
City	NULL
,	NULL
IA	NULL
)	NULL
for	NULL
providing	NULL
FasL	NULL
promoter-luciferase	NULL
constructs	NULL
and	NULL
JT/	NULL
mut	NULL
CD95	NULL
(	NULL
DD3	NULL
)	NULL
cell	NULL
line	NULL
.	NULL

R	NULL
.K	NULL
.	NULL

Srivastava	NULL
is	NULL
a	NULL
recipient	NULL
of	NULL
the	NULL
National	NULL
R	NULL
esearch	NULL
Council	NULL
Fellowship	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
R.K.	NULL
Srivastava	NULL
,	NULL
Laboratory	NULL
of	NULL
Immunology	NULL
,	NULL
National	NULL
Institute	NULL
on	NULL
Aging	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
5600	NULL
Nathan	NULL
Shock	NULL
Dr.	NULL
,	NULL
Box	NULL
9	NULL
,	NULL
Baltimore	NULL
,	NULL
MD	NULL
21224-6825	NULL
.	NULL

Phone	NULL
:	NULL
410-558-8480	NULL
;	NULL
Fax	NULL
:	NULL
410-558-8284	NULL
;	NULL
E-mail	NULL
:	NULL
rakeshs	NULL
@	NULL
vax.gre.nia.nih.gov	NULL
Submitted	NULL
:	NULL
2	NULL
February	NULL
1999	NULL
-	NULL
Revised	NULL
:	NULL
19	NULL
May	NULL
1999	NULL
-	NULL
Aaepted	NULL
:	NULL
25	NULL
May	NULL
1999	NULL
References	NULL
1	NULL
.	NULL

Watanabe-Fukunaga	NULL
,	NULL
R.	NULL
,	NULL
CI	NULL
.	NULL

Brannan	NULL
,	NULL
N.G	NULL
.	NULL

Copeland	NULL
,	NULL
N.A	NULL
.	NULL

Jenkins	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1992	NULL
.	NULL

Lymphoproliferation	NULL
disorder	NULL
in	NULL
mice	NULL
explained	NULL
by	NULL
defects	NULL
in	NULL
Fas	NULL
antigen	NULL
that	NULL
medi-	NULL
ates	NULL
apoptosis	NULL
.	NULL

Nature	NULL
.	NULL

356:314-317	NULL
.	NULL

2	NULL
.	NULL

Leithauser	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
Dhein	NULL
,	NULL
G.	NULL
Mechtersheimer	NULL
,	NULL
K.	NULL
Koretz	NULL
,	NULL
S.	NULL
Bruderlein	NULL
,	NULL
C.	NULL
Henne	NULL
,	NULL
A.	NULL
Schmidt	NULL
,	NULL
KM	NULL
.	NULL

Debatin	NULL
,	NULL
P.H	NULL
.	NULL

262	NULL
-	NULL
Inhibition	NULL
of	NULL
Fas	NULL
Ligand	NULL
Transcription	NULL
by	NULL
Bcl-2	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

Krammer	NULL
,	NULL
and	NULL
P.	NULL
Moller	NULL
.	NULL

1993	NULL
.	NULL

Constitutive	NULL
and	NULL
induced	NULL
expression	NULL
of	NULL
APO-1	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
nerve	NULL
growth	NULL
factor/	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
superfamily	NULL
,	NULL
in	NULL
normal	NULL
and	NULL
neoplastic	NULL
cells	NULL
.	NULL

Lab	NULL
.	NULL

Invest	NULL
.	NULL

69:415-429.	NULL
.	NULL

French	NULL
,	NULL
LE	NULL
.	NULL

,	NULL
M.	NULL
Hahne	NULL
,	NULL
I.	NULL
Viard	NULL
,	NULL
G.	NULL
Radlgruber	NULL
,	NULL
R.	NULL
Zanone	NULL
,	NULL
K.	NULL
Becker	NULL
,	NULL
C.	NULL
Muller	NULL
,	NULL
and	NULL
J.	NULL
Tschopp	NULL
.	NULL

1996	NULL
.	NULL

Fas	NULL
and	NULL
Fas	NULL
ligand	NULL
in	NULL
embryos	NULL
and	NULL
adult	NULL
mice	NULL
:	NULL
ligand	NULL
expression	NULL
in	NULL
several	NULL
immune-privileged	NULL
tissues	NULL
and	NULL
coexpression	NULL
in	NULL
adult	NULL
tissues	NULL
characterized	NULL
by	NULL
apoptotic	NULL
cell	NULL
turnover	NULL
.	NULL

J	NULL
Céll	NULL
Biol	NULL
.	NULL

133:335-343.	NULL
.	NULL

Rouvier	NULL
,	NULL
E.	NULL
,	NULL
MF	NULL
.	NULL

Luciani	NULL
,	NULL
and	NULL
P.	NULL
Golstein	NULL
.	NULL

1993	NULL
.	NULL

Fas	NULL
in	NULL
volvement	NULL
in	NULL
Ca®*-independent	NULL
T	NULL
cell-mediated	NULL
cytotoxicity	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177:195-200.	NULL
.	NULL

Arase	NULL
,	NULL
H.	NULL
,	NULL
N.	NULL
Arase	NULL
,	NULL
and	NULL
T.	NULL
Saito	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
mediated	NULL
cyto-	NULL
toxicity	NULL
by	NULL
freshly	NULL
isolated	NULL
natural	NULL
killer	NULL
cells	NULL
J	NULL
Exp	NULL
.	NULL

Med	NULL
181:1235-1238.	NULL
.	NULL

Tanaka	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Suda	NULL
,	NULL
K.	NULL
Haze	NULL
,	NULL
N.	NULL
Nakamura	NULL
,	NULL
K.	NULL
Sato	NULL
,	NULL
F.	NULL
Kimura	NULL
,	NULL
K.	NULL
Motoyoshi	NULL
,	NULL
M.	NULL
Mizuki	NULL
,	NULL
S.	NULL
Tagawa	NULL
,	NULL
S.	NULL
Ohga	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

Fas	NULL
ligand	NULL
in	NULL
human	NULL
serum	NULL
.	NULL

N	NULL
@	NULL
.	NULL

Med	NULL
.	NULL

2:317-322.	NULL
.	NULL

French	NULL
,	NULL
LE	NULL
.	NULL

,	NULL
A.	NULL
Wilson	NULL
,	NULL
M.	NULL
Hahne	NULL
,	NULL
I.	NULL
Viard	NULL
,	NULL
J.	NULL
Tschopp	NULL
,	NULL
and	NULL
H.R	NULL
.	NULL

MacDonald	NULL
.	NULL

1997	NULL
.	NULL

Fas	NULL
ligand	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
nonlymphoid	NULL
thymic	NULL
components	NULL
in	NULL
situ	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

159:2196-2202.	NULL
.	NULL

Watanabe-Fukunaga	NULL
,	NULL
R.	NULL
,	NULL
C.I	NULL
.	NULL

Brannan	NULL
,	NULL
N.	NULL
Itoh	NULL
,	NULL
S.	NULL
Yone-	NULL
hara	NULL
,	NULL
N.G	NULL
.	NULL

Copeland	NULL
,	NULL
N.A	NULL
.	NULL

Jenkins	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
cDNA	NULL
structure	NULL
,	NULL
expression	NULL
,	NULL
and	NULL
chromosomal	NULL
assignment	NULL
of	NULL
the	NULL
mouse	NULL
Fas	NULL
antigen	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:1274-1279.	NULL
.	NULL

Beligrau	NULL
,	NULL
D.	NULL
,	NULL
D.	NULL
Gold	NULL
,	NULL
H.	NULL
Selawry	NULL
,	NULL
J.	NULL
Moore	NULL
,	NULL
A.	NULL
Franzusoff	NULL
,	NULL
and	NULL
R.C	NULL
.	NULL

Duke	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
role	NULL
for	NULL
CD95	NULL
ligand	NULL
in	NULL
preventing	NULL
graft	NULL
rejection	NULL
.	NULL

Nature	NULL
.	NULL

377:630-632	NULL
.	NULL

Griffith	NULL
,	NULL
TS	NULL
.	NULL

,	NULL
T.	NULL
Brunner	NULL
,	NULL
S.M	NULL
.	NULL

Fletcher	NULL
,	NULL
D.R	NULL
.	NULL

Green	NULL
,	NULL
and	NULL
T.A	NULL
.	NULL

Ferguson	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
ligand-induced	NULL
apoptosis	NULL
as	NULL
a	NULL
mechanism	NULL
of	NULL
immune	NULL
privilege	NULL
.	NULL

Sdene	NULL
.	NULL

270:1189-1192	NULL
.	NULL

Strand	NULL
,	NULL
S.	NULL
,	NULL
W	NULL
.J	NULL
.	NULL

Hofmann	NULL
,	NULL
H.	NULL
Hug	NULL
,	NULL
M.	NULL
Muller	NULL
,	NULL
G.	NULL
Otto	NULL
,	NULL
D.	NULL
Strand	NULL
,	NULL
S.M	NULL
.	NULL

Mariani	NULL
,	NULL
W.	NULL
Stremmel	NULL
,	NULL
P.H	NULL
.	NULL

Krammer	NULL
,	NULL
and	NULL
P.R	NULL
.	NULL

Galle	NULL
.	NULL

1996	NULL
.	NULL

Lymphocyte	NULL
apoptosis	NULL
induced	NULL
by	NULL
CD95	NULL
(	NULL
APO	NULL
-1/	NULL
Fas	NULL
)	NULL
ligand-expressing	NULL
tumor	NULL
cells-a	NULL
mechanism	NULL
of	NULL
immune	NULL
evasion	NULL
?	NULL

Na	NULL
&	NULL
@	NULL
.	NULL

Med	NULL
.	NULL

2:1361-1366	NULL
.	NULL

Hahne	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Rimoldi	NULL
,	NULL
M.	NULL
Schroter	NULL
,	NULL
P.	NULL
Romero	NULL
,	NULL
M.	NULL
Schreier	NULL
,	NULL
LE	NULL
.	NULL

French	NULL
,	NULL
P.	NULL
Schneider	NULL
,	NULL
T.	NULL
Bornand	NULL
,	NULL
A.	NULL
Fontana	NULL
,	NULL
D.	NULL
Lienard	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

Melanoma	NULL
cell	NULL
expression	NULL
of	NULL
Fas	NULL
(	NULL
Apo-1/	NULL
CD95	NULL
)	NULL
ligand	NULL
:	NULL
implications	NULL
for	NULL
tumor	NULL
immune	NULL
escape	NULL
.	NULL

Sdence	NULL
.	NULL

274:1363-1366	NULL
.	NULL

Niehans	NULL
,	NULL
G.A	NULL
.	NULL

,	NULL
T.	NULL
Brunner	NULL
,	NULL
S.P	NULL
.	NULL

Frizelle	NULL
,	NULL
J.C.	NULL
Liston	NULL
,	NULL
C.T	NULL
.	NULL

Salerno	NULL
,	NULL
D.J	NULL
.	NULL

Knapp	NULL
,	NULL
D.R	NULL
.	NULL

Green	NULL
,	NULL
and	NULL
R.A.	NULL
Kratzke	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
lung	NULL
carcinomas	NULL
express	NULL
Fas	NULL
ligand	NULL
.	NULL

Caner	NULL
Res	NULL
.	NULL

57	NULL
:	NULL
1007-1012	NULL
.	NULL

Liu	NULL
,	NULL
Q.Y	NULL
.	NULL

,	NULL
M.A	NULL
.	NULL

Rubin	NULL
,	NULL
C.	NULL
Omene	NULL
,	NULL
S.	NULL
Lederman	NULL
,	NULL
and	NULL
C.A	NULL
.	NULL

Stein	NULL
.	NULL

1998	NULL
.	NULL

Fas	NULL
ligand	NULL
is	NULL
constitutively	NULL
secreted	NULL
by	NULL
prostate	NULL
cancer	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Clin	NULL
.	NULL

Carer	NULL
Res	NULL
.	NULL

4:1803-1811	NULL
.	NULL

Nagata	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
P.	NULL
Golstein	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
Fas	NULL
death	NULL
factor	NULL
.	NULL

Sa-ence	NULL
.	NULL

267:1449-1456	NULL
.	NULL

Nagata	NULL
,	NULL
S.	NULL
1996	NULL
.	NULL

A	NULL
death	NULL
factor-the	NULL
other	NULL
side	NULL
of	NULL
the	NULL
coin	NULL
.	NULL

Behring	NULL
.	NULL

Inst	NULL
.	NULL

Mitt	NULL
.	NULL

97:1-11	NULL
.	NULL

Kondo	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Suda	NULL
,	NULL
H.	NULL
Fukuyama	NULL
,	NULL
M.	NULL
Adachi	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1997	NULL
.	NULL

Essential	NULL
roles	NULL
of	NULL
the	NULL
Fas	NULL
ligand	NULL
in	NULL
the	NULL
development	NULL
of	NULL
hepatitis	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

3:409-413	NULL
.	NULL

Chervonsky	NULL
,	NULL
A.V	NULL
.	NULL

,	NULL
Y.	NULL
Wang	NULL
,	NULL
F.S	NULL
.	NULL

Wong	NULL
,	NULL
I.	NULL
Visintin	NULL
,	NULL
R.A.	NULL
Flavell	NULL
,	NULL
C.A	NULL
.	NULL

Janeway	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
L.A.	NULL
Matis	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
role	NULL
of	NULL
Fas	NULL
in	NULL
autoimmune	NULL
diabetes	NULL
.	NULL

Cell	NULL
.	NULL

89:17-24	NULL
.	NULL

Giordano	NULL
,	NULL
C.	NULL
,	NULL
G.	NULL
Stassi	NULL
,	NULL
R.	NULL
De	NULL
Maria	NULL
,	NULL
M.	NULL
Todaro	NULL
,	NULL
P.	NULL
Rich-iusa	NULL
,	NULL
G.	NULL
Papoff	NULL
,	NULL
G.	NULL
R	NULL
uberti	NULL
,	NULL
M.	NULL
Bagnasco	NULL
,	NULL
R.	NULL
Testi	NULL
,	NULL
and	NULL
A.	NULL
Galluzzo	NULL
.	NULL

1997	NULL
.	NULL

Potential	NULL
involvement	NULL
of	NULL
Fas	NULL
and	NULL
its	NULL
ligand	NULL
in	NULL
263	NULL
-	NULL
Srivastava	NULL
et	NULL
al	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36.	NULL
the	NULL
pathogenesis	NULL
of	NULL
Hashimoto	NULL
's	NULL
thyroiditis	NULL
Sdence	NULL
.	NULL

275	NULL
:	NULL
960-963	NULL
.	NULL

Ito	NULL
,	NULL
MR.	NULL
,	NULL
S.	NULL
Terasaki	NULL
,	NULL
J.	NULL
Itoh	NULL
,	NULL
H.	NULL
Katoh	NULL
,	NULL
S.	NULL
Yonehara	NULL
,	NULL
and	NULL
M.	NULL
Nose	NULL
.	NULL

1997	NULL
.	NULL

Rheumatic	NULL
diseases	NULL
in	NULL
an	NULL
MRL	NULL
strain	NULL
of	NULL
mice	NULL
with	NULL
a	NULL
deficit	NULL
in	NULL
the	NULL
functional	NULL
Fas	NULL
ligand	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

40:1054-1063	NULL
.	NULL

Itoh	NULL
,	NULL
N.	NULL
,	NULL
A.	NULL
Imagawa	NULL
,	NULL
T.	NULL
Hanafusa	NULL
,	NULL
M.	NULL
Waguri	NULL
,	NULL
K.	NULL
Yama-moto	NULL
,	NULL
H.	NULL
Iwahashi	NULL
,	NULL
M.	NULL
Moriwaki	NULL
,	NULL
H.	NULL
Nakajima	NULL
,	NULL
J.	NULL
Miya-gawa	NULL
,	NULL
M.	NULL
Namba	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Requirement	NULL
of	NULL
Fas	NULL
for	NULL
the	NULL
development	NULL
of	NULL
autoimmune	NULL
diabetes	NULL
in	NULL
nonobese	NULL
diabetic	NULL
mice	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:613-618	NULL
.	NULL

Hickman	NULL
,	NULL
J.A	NULL
.	NULL

1992	NULL
.	NULL

Apoptosis	NULL
induced	NULL
by	NULL
anticancer	NULL
drugs	NULL
.	NULL

Cancer	NULL
Metastasis	NULL
Rev	NULL
.	NULL

11:121-139	NULL
.	NULL

Pietenpol	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
N.	NULL
Papadopoulos	NULL
,	NULL
S.	NULL
Markowitz	NULL
,	NULL
J.K.	NULL
Will-son	NULL
,	NULL
KW	NULL
.	NULL

Kinzler	NULL
,	NULL
and	NULL
B.	NULL
Vogelstein	NULL
.	NULL

1994	NULL
.	NULL

Paradoxical	NULL
inhibition	NULL
of	NULL
solid	NULL
tumor	NULL
cell	NULL
growth	NULL
by	NULL
bel2	NULL
.	NULL

Caner	NULL
Res	NULL
.	NULL

54	NULL
:	NULL
3714-3717.	NULL
.	NULL

Haldar	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Basu	NULL
,	NULL
and	NULL
C.M	NULL
.	NULL

Croce	NULL
.	NULL

1997	NULL
.	NULL

Bcl2	NULL
is	NULL
the	NULL
guardian	NULL
of	NULL
microtubule	NULL
integrity	NULL
.	NULL

Caner	NULL
Res	NULL
.	NULL

57:229-233	NULL
.	NULL

Srivastava	NULL
,	NULL
R	NULL
.K	NULL
.	NULL

,	NULL
A.R	NULL
.	NULL

Srivastava	NULL
,	NULL
S.J	NULL
.	NULL

Korsmeyer	NULL
,	NULL
M.	NULL
Nester-ova	NULL
,	NULL
Y.8	NULL
.	NULL

Cho-Chung	NULL
,	NULL
and	NULL
D.L	NULL
.	NULL

Longo	NULL
.	NULL

1998	NULL
.	NULL

Involvement	NULL
of	NULL
microtubules	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
Bcel2	NULL
phosphorylation	NULL
and	NULL
apoptosis	NULL
through	NULL
cyclic	NULL
AMP-dependent	NULL
protein	NULL
kinase	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:3509-3517	NULL
.	NULL

McDonnell	NULL
,	NULL
T.J.	NULL
,	NULL
and	NULL
S.J	NULL
.	NULL

Korsmeyer	NULL
.	NULL

1991	NULL
.	NULL

Progression	NULL
from	NULL
lymphoid	NULL
hyperplasia	NULL
to	NULL
high-grade	NULL
malignant	NULL
lymphoma	NULL
in	NULL
mice	NULL
transgenic	NULL
for	NULL
the	NULL
t	NULL
(	NULL
14	NULL
;	NULL
18	NULL
)	NULL
.	NULL

Nature	NULL
349	NULL
:	NULL
254-256	NULL
.	NULL

Strasser	NULL
,	NULL
A.	NULL
,	NULL
AW	NULL
.	NULL

Harris	NULL
and	NULL
S.	NULL
Cory	NULL
.	NULL

1993	NULL
.	NULL

E	NULL
mu-bel-2	NULL
transgene	NULL
facilitates	NULL
spontaneous	NULL
transformation	NULL
of	NULL
early	NULL
pre-B	NULL
and	NULL
immunoglobulin-secreting	NULL
cells	NULL
but	NULL
not	NULL
T	NULL
cells	NULL
One	NULL
gene	NULL
.	NULL

8:1-9	NULL
.	NULL

Linette	NULL
,	NULL
G.P	NULL
.	NULL

,	NULL
JL	NULL
.	NULL

Hess	NULL
,	NULL
C.L	NULL
.	NULL

Sentman	NULL
,	NULL
and	NULL
S.J	NULL
.	NULL

Korsmeyer	NULL
.	NULL

1995	NULL
.	NULL

Peripheral	NULL
T-cell	NULL
lymphoma	NULL
in	NULL
Ickpr-bel-2	NULL
transgenic	NULL
mice	NULL
.	NULL

Blood	NULL
.	NULL

86:1255-1260	NULL
.	NULL

Veis	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
C.M	NULL
.	NULL

Sorenson	NULL
,	NULL
JR.	NULL
Shutter	NULL
,	NULL
and	NULL
S.J	NULL
.	NULL

Korsmeyer	NULL
.	NULL

1993	NULL
.	NULL

Bcl-2-deficient	NULL
mice	NULL
demonstrate	NULL
fulminant	NULL
lymphoid	NULL
apoptosis	NULL
,	NULL
polycystic	NULL
kidneys	NULL
,	NULL
and	NULL
hypopigmented	NULL
hair	NULL
.	NULL

Céll	NULL
.	NULL

75:229-240.	NULL
.	NULL

Ma	NULL
,	NULL
A.	NULL
,	NULL
J.C.	NULL
Pena	NULL
,	NULL
B.	NULL
Chang	NULL
,	NULL
E.	NULL
Margosian	NULL
,	NULL
L.	NULL
Davidson	NULL
,	NULL
FW	NULL
.	NULL

Alt	NULL
,	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
.	NULL

1995	NULL
.	NULL

Belx	NULL
regulates	NULL
the	NULL
survival	NULL
of	NULL
double-positive	NULL
thymocytes	NULL
.	NULL

Pme	NULL
Nal	NULL
.	NULL

Aad	NULL
.	NULL

Sd	NULL
.	NULL

USA	NULL
.	NULL

92:4763-4767	NULL
.	NULL

Motoyama	NULL
,	NULL
N.	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
K.A	NULL
.	NULL

Roth	NULL
,	NULL
H.	NULL
Sawa	NULL
,	NULL
K.	NULL
Na-kayama	NULL
,	NULL
I.	NULL
Negishi	NULL
,	NULL
S.	NULL
Senju	NULL
,	NULL
Q.	NULL
Zhang	NULL
,	NULL
S.	NULL
Fujii	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Massive	NULL
cell	NULL
death	NULL
of	NULL
immature	NULL
hematopoietic	NULL
cells	NULL
and	NULL
neurons	NULL
in	NULL
Bcl-x-defficient	NULL
mice	NULL
.	NULL

Saerce	NULL
.	NULL

267:1506-1510	NULL
.	NULL

Kumar	NULL
,	NULL
N.	NULL
1981	NULL
.	NULL

Taxol-induced	NULL
polymerization	NULL
of	NULL
purified	NULL
tubulin	NULL
.	NULL

Mechanism	NULL
of	NULL
action	NULL
.	NULL

J	NULL
Biol	NULL
Chen	NULL
.	NULL

256:10435-10441	NULL
.	NULL

Blagosklonny	NULL
,	NULL
M.V	NULL
.	NULL

,	NULL
P.	NULL
Giannakakou	NULL
,	NULL
W.S	NULL
.	NULL

el-Deiry	NULL
,	NULL
D.G	NULL
.	NULL

Kingston	NULL
,	NULL
P.I	NULL
.	NULL

Higgs	NULL
,	NULL
L.	NULL
Neckers	NULL
,	NULL
and	NULL
T.	NULL
Fojo	NULL
.	NULL

1997	NULL
.	NULL

R	NULL
af-1/	NULL
bel-2	NULL
phosphorylation	NULL
:	NULL
a	NULL
step	NULL
from	NULL
microtubule	NULL
damage	NULL
to	NULL
cell	NULL
death	NULL
.	NULL

Carer	NULL
Res	NULL
.	NULL

57:130-135	NULL
.	NULL

Rodi	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
R.W	NULL
.	NULL

Janes	NULL
,	NULL
H.J	NULL
.	NULL

Sanganee	NULL
,	NULL
R.A.	NULL
Holton	NULL
,	NULL
B.A	NULL
.	NULL

Wallace	NULL
,	NULL
and	NULL
L.	NULL
Makowski	NULL
.	NULL

1999	NULL
.	NULL

Screening	NULL
of	NULL
a	NULL
library	NULL
of	NULL
phage-displayed	NULL
peptides	NULL
identifies	NULL
human	NULL
bel-2	NULL
as	NULL
a	NULL
taxol-binding	NULL
protein	NULL
.	NULL

J	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

285:197-203	NULL
.	NULL

Haldar	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Basu	NULL
,	NULL
and	NULL
C.M	NULL
.	NULL

Croce	NULL
.	NULL

1998	NULL
.	NULL

Serine-70	NULL
is	NULL
one	NULL
of	NULL
the	NULL
critical	NULL
sites	NULL
for	NULL
drug-induced	NULL
Bcl2	NULL
phosphorylation	NULL
in	NULL
cancer	NULL
cells	NULL
.	NULL

Carer	NULL
Res	NULL
.	NULL

58:1609-1615	NULL
.	NULL

Schreiber	NULL
,	NULL
SL	NULL
.	NULL

,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Immunol	NULL
Today	NULL
.	NULL

13	NULL
:	NULL
37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

136-142	NULL
.	NULL

Weiss	NULL
,	NULL
D.L	NULL
.	NULL

,	NULL
J.	NULL
Hural	NULL
,	NULL
D.	NULL
Tara	NULL
,	NULL
L.A.	NULL
Timmerman	NULL
,	NULL
G.	NULL
Henkel	NULL
,	NULL
and	NULL
M.A	NULL
.	NULL

Brown	NULL
.	NULL

1996	NULL
.	NULL

Nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
mast	NULL
cell	NULL
interleukin	NULL
4	NULL
transcription	NULL
complex	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:228-235	NULL
.	NULL

Cockerill	NULL
,	NULL
G.W	NULL
.	NULL

,	NULL
A.G.	NULL
Bert	NULL
,	NULL
G.R	NULL
.	NULL

Ryan	NULL
,	NULL
JR.	NULL
Gamble	NULL
,	NULL
M.A	NULL
.	NULL

Vadas	NULL
,	NULL
and	NULL
P.N	NULL
.	NULL

Cockerill	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
and	NULL
E-selectin	NULL
expression	NULL
in	NULL
endothelial	NULL
cells	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
the	NULL
T-cell	NULL
transcription	NULL
factor	NULL
NFAT	NULL
.	NULL

Blood	NULL
.	NULL

86:2689-2698	NULL
.	NULL

Boss	NULL
,	NULL
V.	NULL
,	NULL
KL	NULL
.	NULL

Abbott	NULL
,	NULL
X.F	NULL
.	NULL

Wang	NULL
,	NULL
G.K.	NULL
Pavlath	NULL
,	NULL
and	NULL
T.J.	NULL
Murphy	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
cyclosporin	NULL
A-sensitive	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
proteins	NULL
are	NULL
expressed	NULL
in	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
.	NULL

Differential	NULL
localization	NULL
of	NULL
NFAT	NULL
isoforms	NULL
and	NULL
induction	NULL
of	NULL
NFAT-mediated	NULL
transcription	NULL
by	NULL
phospholipase	NULL
C-coupled	NULL
cell	NULL
surface	NULL
receptors	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chen	NULL
.	NULL

273:19664-19671	NULL
.	NULL

Ho	NULL
,	NULL
A.M.	NULL
,	NULL
J.	NULL
Jin	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.G	NULL
.	NULL

Hogan	NULL
.	NULL

1994	NULL
.	NULL

Expres	NULL
sion	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT	NULL
p	NULL
in	NULL
a	NULL
neuronal	NULL
cell	NULL
line	NULL
and	NULL
in	NULL
the	NULL
murine	NULL
nervous	NULL
system	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chen	NULL
.	NULL

269:28181-28186	NULL
.	NULL

Hoey	NULL
,	NULL
T.	NULL
,	NULL
Y.L	NULL
.	NULL

Sun	NULL
,	NULL
K.	NULL
Williamson	NULL
,	NULL
and	NULL
X.	NULL
Xu	NULL
.	NULL

1995	NULL
.	NULL

Isolation	NULL
of	NULL
two	NULL
new	NULL
members	NULL
of	NULL
the	NULL
NF-AT	NULL
gene	NULL
family	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
the	NULL
NF-AT	NULL
proteins	NULL
.	NULL

Immunity	NULL
.	NULL

2461-472	NULL
.	NULL

41a.Linette	NULL
,	NULL
G.P	NULL
.	NULL

,	NULL
Y.	NULL
Li	NULL
,	NULL
RK	NULL
.	NULL

Roth	NULL
,	NULL
and	NULL
S.J	NULL
.	NULL

Korsmeyer	NULL
.	NULL

1996	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

Cross	NULL
talk	NULL
between	NULL
cell	NULL
death	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
:	NULL
Bcel-2	NULL
regulates	NULL
NFAT	NULL
-mediated	NULL
activation	NULL
.	NULL

Pre	NULL
Nal	NULL
.	NULL

Aad	NULL
Sd	NULL
.	NULL

USA	NULL
.	NULL

93:9545-9552	NULL
.	NULL

Latinis	NULL
,	NULL
KM	NULL
.	NULL

,	NULL
L.A.	NULL
Norian	NULL
,	NULL
S.L	NULL
.	NULL

Eliason	NULL
,	NULL
and	NULL
G.A	NULL
.	NULL

Koretzky	NULL
.	NULL

1997	NULL
.	NULL

Two	NULL
NFAT	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
participate	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
CD95	NULL
(	NULL
Fas	NULL
)	NULL
ligand	NULL
expression	NULL
in	NULL
activated	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chen	NULL
.	NULL

272:31427-31434	NULL
.	NULL

Latinis	NULL
,	NULL
KM	NULL
.	NULL

,	NULL
LL	NULL
.	NULL

Carr	NULL
,	NULL
E.J	NULL
.	NULL

Peterson	NULL
,	NULL
L.A.	NULL
Norian	NULL
,	NULL
S.L	NULL
.	NULL

Eliason	NULL
,	NULL
and	NULL
G.A	NULL
.	NULL

Koretzky	NULL
.	NULL

1997	NULL
.	NULL

Regulation	NULL
of	NULL
€D95	NULL
(	NULL
Fas	NULL
)	NULL
ligand	NULL
expression	NULL
by	NULL
TCR	NULL
-mediated	NULL
signaling	NULL
events	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

158:4602-4611.	NULL
.	NULL

Holtz-Heppelmann	NULL
,	NULL
C.J	NULL
.	NULL

,	NULL
A.	NULL
Algeciras	NULL
A.D.	NULL
Badley	NULL
,	NULL
and	NULL
C.V.	NULL
Paya	NULL
.	NULL

1998	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
FasL	NULL
promoter-enhancer	NULL
region	NULL
.	NULL

J	NULL
Biol	NULL
Chen	NULL
.	NULL

273:4416-4423	NULL
.	NULL

Clipstone	NULL
,	NULL
N.A	NULL
.	NULL

,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
calcineurin	NULL
as	NULL
a	NULL
key	NULL
signalling	NULL
enzyme	NULL
in	NULL
T-lymphocyte	NULL
activation	NULL
.	NULL

Nature	NULL
.	NULL

357:695-697	NULL
.	NULL

Peterson	NULL
,	NULL
E.J	NULL
.	NULL

,	NULL
K.M	NULL
.	NULL

Latinis	NULL
,	NULL
and	NULL
G.A	NULL
.	NULL

Koretzky	NULL
.	NULL

1998	NULL
.	NULL

Molecular	NULL
characterization	NULL
of	NULL
a	NULL
CD95	NULL
signaling	NULL
mutant	NULL
.	NULL

A	NULL
thrifis	NULL
Rheum	NULL
.	NULL

41:1047-1053	NULL
.	NULL

Anel	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Buferne	NULL
,	NULL
C.	NULL
Boyer	NULL
,	NULL
A.M.	NULL
Schmitt-	NULL
Verhulst	NULL
,	NULL
and	NULL
P.	NULL
Golstein	NULL
.	NULL

1994	NULL
.	NULL

T	NULL
cell	NULL
receptor-induced	NULL
Fas	NULL
ligand	NULL
expression	NULL
in	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
clones	NULL
is	NULL
blocked	NULL
by	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
and	NULL
cyclosporin	NULL
A.	NULL
Eur	NULL
J	NULL
Immunol	NULL
.	NULL

24:2469-2476	NULL
.	NULL

Alderson	NULL
,	NULL
MR.	NULL
,	NULL
TW	NULL
.	NULL

Tough	NULL
,	NULL
T.	NULL
Davis	NULL
Smith	NULL
,	NULL
S.	NULL
Braddy	NULL
,	NULL
B.	NULL
Falk	NULL
,	NULL
K.A	NULL
.	NULL

Schooley	NULL
,	NULL
R.G	NULL
.	NULL

Goodwin	NULL
,	NULL
C.A	NULL
.	NULL

Smith	NULL
,	NULL
F.	NULL
R	NULL
amsdell	NULL
,	NULL
and	NULL
D.H.	NULL
Lynch	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
ligand	NULL
mediates	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:71-77	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
R.J.	NULL
Mogil	NULL
,	NULL
D.	NULL
LaFace	NULL
,	NULL
N.J.	NULL
Yoo	NULL
,	NULL
A.	NULL
Mahboubi	NULL
,	NULL
F.	NULL
Echeverri	NULL
,	NULL
S.J	NULL
.	NULL

Martin	NULL
,	NULL
W.R.	NULL
Force	NULL
,	NULL
D.H.	NULL
Lynch	NULL
,	NULL
C.F	NULL
.	NULL

Ware	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Cell-autonomous	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
Fas-ligand	NULL
interaction	NULL
mediates	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T-cell	NULL
hybridomas	NULL
.	NULL

Nature	NULL
.	NULL

373:441-444	NULL
.	NULL

Dhein	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Walczak	NULL
,	NULL
C.	NULL
Baumler	NULL
,	NULL
K.M	NULL
.	NULL

Debatin	NULL
,	NULL
and	NULL
P.H	NULL
.	NULL

264	NULL
51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

Krammer	NULL
.	NULL

1995	NULL
.	NULL

Autocrine	NULL
T-cell	NULL
suicide	NULL
mediated	NULL
by	NULL
APO-1/	NULL
(	NULL
Fag	NULL
CD95	NULL
)	NULL
.	NULL

Nature	NULL
.	NULL

373:438-441	NULL
.	NULL

Ju	NULL
,	NULL
ST.	NULL
,	NULL
D.J	NULL
.	NULL

Panka	NULL
,	NULL
H.	NULL
Cui	NULL
,	NULL
R.	NULL
Ettinger	NULL
,	NULL
M.	NULL
el-Khatib	NULL
,	NULL
D.H.	NULL
Sherr	NULL
,	NULL
B.Z	NULL
.	NULL

Stanger	NULL
,	NULL
and	NULL
A.	NULL
Marshak-R	NULL
othstein	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
{	NULL
CD95	NULL
)	NULL
/	NULL
FasL	NULL
interactions	NULL
required	NULL
for	NULL
programmed	NULL
cell	NULL
death	NULL
after	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
.	NULL

373:444-448	NULL
.	NULL

Fulda	NULL
,	NULL
S.	NULL
,	NULL
H.	NULL
Sieverts	NULL
,	NULL
C.	NULL
Friesen	NULL
,	NULL
I.	NULL
Herr	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Debatin	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
CD95	NULL
(	NULL
APO-1/Fas	NULL
)	NULL
system	NULL
mediates	NULL
drug-induced	NULL
apoptosis	NULL
in	NULL
neuroblastoma	NULL
cells	NULL
Caner	NULL
Res	NULL
.	NULL

57	NULL
:	NULL
3823-3829	NULL
.	NULL

Reap	NULL
,	NULL
EA	NULL
.	NULL

,	NULL
K.	NULL
Roof	NULL
,	NULL
K.	NULL
Maynor	NULL
,	NULL
M.	NULL
Borrero	NULL
,	NULL
J.	NULL
Booker	NULL
,	NULL
and	NULL
P.L	NULL
.	NULL

Cohen	NULL
.	NULL

1997	NULL
.	NULL

Radiation	NULL
and	NULL
stress-induced	NULL
apopto-sis	NULL
:	NULL
a	NULL
role	NULL
for	NULL
Fas	NULL
Fas	NULL
ligand	NULL
interactions	NULL
.	NULL

Proc	NULL
Nal	NULL
.	NULL

Aad	NULL
.	NULL

Sq	NULL
.	NULL

USA	NULL
.	NULL

94:5750-5755	NULL
.	NULL

Rehemtulla	NULL
,	NULL
A.	NULL
,	NULL
C.A	NULL
.	NULL

Hamilton	NULL
,	NULL
A.M.	NULL
Chinnaiyan	NULL
,	NULL
and	NULL
V.M	NULL
.	NULL

Dixit	NULL
.	NULL

1997	NULL
.	NULL

Ultraviolet	NULL
radiation-induced	NULL
apoptosis	NULL
is	NULL
mediated	NULL
by	NULL
activation	NULL
of	NULL
CD-95	NULL
(	NULL
Fay	NULL
APO-1	NULL
)	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

272:25783-25786	NULL
.	NULL

Rothenberg	NULL
,	NULL
EV	NULL
.	NULL

,	NULL
and	NULL
S	NULL
$	NULL
.B	NULL
.	NULL

Ward	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
dynamic	NULL
assembly	NULL
of	NULL
diverse	NULL
transcription	NULL
factors	NULL
integrates	NULL
activation	NULL
and	NULL
cell-type	NULL
information	NULL
for	NULL
interleukin	NULL
2	NULL
gene	NULL
regulation	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

93:9358-9365	NULL
.	NULL

Rao	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
Luo	NULL
,	NULL
and	NULL
P.G	NULL
.	NULL

Hogan	NULL
.	NULL

1997	NULL
.	NULL

Transcription	NULL
factors	NULL
of	NULL
the	NULL
NFAT	NULL
family	NULL
:	NULL
regulation	NULL
and	NULL
function	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15707-17147	NULL
.	NULL

Shibasaki	NULL
,	NULL
F.	NULL
,	NULL
E.	NULL
Kondo	NULL
,	NULL
T.	NULL
Akagi	NULL
,	NULL
and	NULL
F.	NULL
McKeon	NULL
.	NULL

1997	NULL
.	NULL

Suppression	NULL
of	NULL
signalling	NULL
through	NULL
transcription	NULL
factor	NULL
NF-	NULL
AT	NULL
by	NULL
interactions	NULL
between	NULL
calcineurin	NULL
and	NULL
Bcl-2	NULL
.	NULL

Nature	NULL
386	NULL
:	NULL
728-731	NULL
.	NULL

Thuret-Carnahan	NULL
,	NULL
J.	NULL
,	NULL
JL	NULL
.	NULL

Bossu	NULL
,	NULL
A.	NULL
Feltz	NULL
,	NULL
K.	NULL
Langley	NULL
,	NULL
and	NULL
D.	NULL
Aunis	NULL
1985	NULL
.	NULL

Effect	NULL
of	NULL
taxol	NULL
on	NULL
secretory	NULL
cells	NULL
:	NULL
functional	NULL
,	NULL
morphological	NULL
,	NULL
and	NULL
electrophysiological	NULL
correlates	NULL
.	NULL

J	NULL
Cell	NULL
Biol	NULL
.	NULL

100:1863-1874	NULL
.	NULL

Srivastava	NULL
,	NULL
R	NULL
.K	NULL
.	NULL

,	NULL
Q.S	NULL
.	NULL

Mi	NULL
,	NULL
J.M	NULL
.	NULL

Hardwick	NULL
,	NULL
and	NULL
D.L	NULL
.	NULL

Longo	NULL
.	NULL

1999	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
loop	NULL
region	NULL
of	NULL
Bcl-2	NULL
completely	NULL
blocks	NULL
paclitaxel-induced	NULL
apoptosis	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Aad	NULL
.	NULL

Sd	NULL
.	NULL

USA	NULL
.	NULL

96	NULL
:	NULL
3775-3780	NULL
.	NULL

Chang	NULL
,	NULL
B.S	NULL
.	NULL

,	NULL
A.J	NULL
.	NULL

Minn	NULL
,	NULL
SW.	NULL
Muchmore	NULL
,	NULL
S.W	NULL
.	NULL

Fesik	NULL
,	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
.	NULL

1997	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
novel	NULL
regulatory	NULL
domain	NULL
in	NULL
Bcl-X	NULL
;	NULL
,	NULL
and	NULL
Bcl-2	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

16:968-977	NULL
.	NULL

O'Connell	NULL
,	NULL
J.	NULL
,	NULL
G.C	NULL
.	NULL

O'Sullivan	NULL
,	NULL
JK	NULL
.	NULL

Collins	NULL
,	NULL
and	NULL
F.	NULL
Shana-han	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
Fas	NULL
counterattack	NULL
:	NULL
Fas	NULL
mediated	NULL
T	NULL
cell	NULL
killing	NULL
by	NULL
colon	NULL
cancer	NULL
cells	NULL
expressing	NULL
Fas	NULL
ligand	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184	NULL
:	NULL
1075-1082	NULL
.	NULL

Strand	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
P.R	NULL
.	NULL

Galle	NULL
.	NULL

1998	NULL
.	NULL

Immune	NULL
evasion	NULL
by	NULL
tu-mours	NULL
:	NULL
involvement	NULL
of	NULL
the	NULL
CD95	NULL
(	NULL
APO-1/	NULL
Fas	NULL
)	NULL
system	NULL
and	NULL
its	NULL
clinical	NULL
implications	NULL
.	NULL

Mol	NULL
.	NULL

Med	NULL
.	NULL

Today	NULL
.	NULL

4:63-68	NULL
.	NULL

Strand	NULL
,	NULL
S.	NULL
,	NULL
W.J	NULL
.	NULL

Hofmann	NULL
,	NULL
A.	NULL
Grambihler	NULL
,	NULL
H.	NULL
Hug	NULL
,	NULL
M.	NULL
Volkmann	NULL
,	NULL
G.	NULL
Otto	NULL
,	NULL
H.	NULL
Wesch	NULL
,	NULL
S.M	NULL
.	NULL

Mariani	NULL
,	NULL
V.	NULL
Hack	NULL
,	NULL
W.	NULL
Stremmel	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

Hepatic	NULL
failure	NULL
and	NULL
liver	NULL
cell	NULL
damage	NULL
in	NULL
acute	NULL
Wilson	NULL
's	NULL
disease	NULL
involve	NULL
CD95	NULL
(	NULL
APO-1/	NULL
Fas	NULL
)	NULL
mediated	NULL
apoptosis	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

4:588-593	NULL
.	NULL

Wallach	NULL
,	NULL
D.	NULL
,	NULL
M.	NULL
Boldin	NULL
,	NULL
E.	NULL
Varfolomeev	NULL
,	NULL
R.	NULL
Beyaert	NULL
,	NULL
P.	NULL
Vandenabeele	NULL
,	NULL
and	NULL
W.	NULL
Fiers	NULL
.	NULL

1997	NULL
.	NULL

Cell	NULL
death	NULL
induction	NULL
by	NULL
receptors	NULL
of	NULL
the	NULL
TNF	NULL
family	NULL
:	NULL
towards	NULL
a	NULL
molecular	NULL
under-standing	NULL
.	NULL

FEBS	NULL
Let	NULL
.	NULL

410:96-106	NULL
.	NULL

Los	NULL
,	NULL
M.	NULL
,	NULL
I.	NULL
Herr	NULL
,	NULL
C.	NULL
Friesen	NULL
,	NULL
S.	NULL
Fulda	NULL
,	NULL
K.	NULL
Schulze-Osthoff	NULL
,	NULL
and	NULL
KM	NULL
.	NULL

Debatin	NULL
.	NULL

1997	NULL
.	NULL

Cross-resistance	NULL
of	NULL
CD95-	NULL
and	NULL
drug-induced	NULL
apoptosis	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
deficient	NULL
activation	NULL
of	NULL
caspases	NULL
(	NULL
ICE/	NULL
Ced-3	NULL
proteases	NULL
)	NULL
.	NULL

Blood	NULL
.	NULL

90:3118-3129	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
N.J.	NULL
Yoo	NULL
,	NULL
T.S	NULL
.	NULL

Griffith	NULL
,	NULL
T.A	NULL
.	NULL

Ferguson	NULL
,	NULL
and	NULL
D.R	NULL
.	NULL

Green	NULL
.	NULL

1996	NULL
.	NULL

Regulation	NULL
of	NULL
CD95	NULL
ligand	NULL
expression	NULL
:	NULL
a	NULL
Inhibition	NULL
of	NULL
Fas	NULL
Ligand	NULL
Transcription	NULL
by	NULL
Bel-2	NULL
67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71.	NULL
key	NULL
element	NULL
in	NULL
immune	NULL
regulation	NULL
?	NULL

Behring	NULL
Inst	NULL
.	NULL

Mitt	NULL
.	NULL

97	NULL
:	NULL
161-174	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
N.J.	NULL
Yoo	NULL
,	NULL
D.	NULL
LaFace	NULL
,	NULL
C.F	NULL
.	NULL

Ware	NULL
,	NULL
and	NULL
D.R	NULL
.	NULL

Green	NULL
.	NULL

1996	NULL
.	NULL

Activation-induced	NULL
cell	NULL
death	NULL
in	NULL
murine	NULL
T	NULL
cell	NULL
hybridomas	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
versus	NULL
Fas	NULL
ligand	NULL
expression	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

8:1017-1026	NULL
.	NULL

Ruff	NULL
,	NULL
V.A	NULL
.	NULL

,	NULL
and	NULL
KL	NULL
.	NULL

Leach	NULL
.	NULL

1995	NULL
.	NULL

Direct	NULL
demonstration	NULL
of	NULL
NFAT	NULL
p	NULL
dephosphorylation	NULL
and	NULL
nuclear	NULL
localization	NULL
in	NULL
activated	NULL
HT-2	NULL
cells	NULL
using	NULL
a	NULL
specific	NULL
NFAT	NULL
p	NULL
polyclonal	NULL
antibody	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:22602-22607	NULL
.	NULL

Timmerman	NULL
,	NULL
L.A.	NULL
,	NULL
N.A	NULL
.	NULL

Clipstone	NULL
,	NULL
S.N	NULL
.	NULL

Ho	NULL
,	NULL
J.P.	NULL
Northrop	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1996	NULL
.	NULL

R	NULL
apid	NULL
shuttling	NULL
of	NULL
NF-AT	NULL
in	NULL
dis	NULL
crimination	NULL
of	NULL
Ca**	NULL
signals	NULL
and	NULL
immunosuppression	NULL
.	NULL

Nature	NULL
.	NULL

383:837-840	NULL
.	NULL

Beals	NULL
,	NULL
C.R	NULL
.	NULL

,	NULL
C.M	NULL
.	NULL

Sheridan	NULL
,	NULL
C.W	NULL
.	NULL

Turck	NULL
,	NULL
P.	NULL
Gardner	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1997	NULL
.	NULL

Nuclear	NULL
export	NULL
of	NULL
NF-AT	NULL
'	NULL
c	NULL
enhanced	NULL
by	NULL
glycogen	NULL
synthase	NULL
kinase-3	NULL
.	NULL

Sdencee	NULL
.	NULL

275:1930-1934	NULL
.	NULL

Boss	NULL
,	NULL
V.	NULL
,	NULL
X.	NULL
Wang	NULL
,	NULL
LF	NULL
.	NULL

Koppelman	NULL
,	NULL
K.	NULL
Xu	NULL
,	NULL
and	NULL
T.J.	NULL
Mur-	NULL
265	NULL
-	NULL
Srivastava	NULL
et	NULL
al	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

75.	NULL
phy	NULL
.	NULL

1998	NULL
.	NULL

Histamine	NULL
induces	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cell-mediated	NULL
transcription	NULL
and	NULL
cyclosporin	NULL
A-sensitive	NULL
inter-leukin-8	NULL
mRNA	NULL
expression	NULL
in	NULL
human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

54:264-272	NULL
.	NULL

Shibasaki	NULL
,	NULL
F.	NULL
,	NULL
E.R	NULL
.	NULL

Price	NULL
,	NULL
D.	NULL
Milan	NULL
,	NULL
and	NULL
F.	NULL
McKeon	NULL
.	NULL

1996	NULL
.	NULL

Role	NULL
of	NULL
kinases	NULL
and	NULL
the	NULL
phosphatase	NULL
calcineurin	NULL
in	NULL
the	NULL
nuclear	NULL
shuttling	NULL
of	NULL
transcription	NULL
factor	NULL
NF-AT4	NULL
.	NULL

Natwre	NULL
382	NULL
:	NULL
370-373	NULL
.	NULL

Hodge	NULL
,	NULL
M.R	NULL
.	NULL

,	NULL
A.M.	NULL
Ranger	NULL
,	NULL
F.	NULL
Charles	NULL
de	NULL
la	NULL
Brousse	NULL
,	NULL
T.	NULL
Hoey	NULL
,	NULL
M.J.	NULL
Grusby	NULL
,	NULL
and	NULL
LH	NULL
.	NULL

Glimcher	NULL
.	NULL

1996	NULL
.	NULL

Hyperprolif-eration	NULL
and	NULL
dysregulation	NULL
of	NULL
IL-4	NULL
expression	NULL
in	NULL
NF-ATp-deficient	NULL
mice	NULL
.	NULL

Immunity	NULL
.	NULL

4:397-405	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

1994	NULL
.	NULL

NF-ATp	NULL
:	NULL
a	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
the	NULL
co-ordinate	NULL
induction	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
.	NULL

15:274-281	NULL
.	NULL

Tsai	NULL
,	NULL
E.Y	NULL
.	NULL

,	NULL
J.	NULL
Yie	NULL
,	NULL
D.	NULL
Thanos	NULL
,	NULL
and	NULL
A.E	NULL
.	NULL

Goldfeld	NULL
.	NULL

1996	NULL
.	NULL

Cell-type-specific	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
gene	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
T	NULL
cells	NULL
by	NULL
NFATp	NULL
and	NULL
ATF-2/	NULL
JUN	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:5232-5244	NULL
.	NULL

